Use of Phage Display Libraries to Select For B-cell Receptor-specific Peptides of Chronic Lymphocytic Leukemia Cells by Chou, Richard M.
Wright State University 
CORE Scholar 
Browse all Theses and Dissertations Theses and Dissertations 
2012 
Use of Phage Display Libraries to Select For B-cell Receptor-
specific Peptides of Chronic Lymphocytic Leukemia Cells 
Richard M. Chou 
Wright State University 
Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all 
 Part of the Pharmacology, Toxicology and Environmental Health Commons 
Repository Citation 
Chou, Richard M., "Use of Phage Display Libraries to Select For B-cell Receptor-specific Peptides of 
Chronic Lymphocytic Leukemia Cells" (2012). Browse all Theses and Dissertations. 612. 
https://corescholar.libraries.wright.edu/etd_all/612 
This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has 
been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE 
Scholar. For more information, please contact library-corescholar@wright.edu. 
 
 
USE OF PHAGE DISPLAY LIBRARIES TO SELECT FOR B-CELL RECEPTOR-
SPECIFIC PEPTIDES OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 
 
A thesis submitted in partial fulfillment of the 
requirements for the degree of 
Master of Science 
 
By 
 
RICHARD CHOU 
B.S. Ohio University, 2007 
 
 
 
 
2012 
Wright State University 
WRIGHT STATE UNIVERSITY 
SCHOOL OF GRADUATE STUDIES 
Date: August, 13
th
 2012 
I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY 
SUPERVISION BY Richard Chou ENTITLED “Use of Phage Display Libraries to 
Select For B-cell Receptor-specific Peptides of Chronic Lymphocytic Leukemia Cells” 
BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE 
DEGREE OF Master of Science. 
 
 
 
__________________________ 
Osvaldo Lopez, Ph.D. 
Thesis Director 
 
Committee on Final Examination 
___________________________ 
Terry Oroszi, M.S. 
Director of Master Program 
__________________________ 
Cheryl Conley, Ph.D 
 
 
 
 
__________________________ 
David Cool, Ph.D. 
___________________________ 
Mariana Morris, Ph.D., Chair 
Department of Pharmacology and  
Toxicology 
 
__________________________ 
Andrew T. Hsu, Ph.D. 
Dean, School of Graduate Studies 
iii 
 
ABSTRACT 
 
 
Chou, Richard. M.S., Department of Pharmacology and Toxicology, Wright State 
University, 2012. Use of Phage Display Libraries to Select For B-cell Receptor-specific 
Peptides of Chronic Lymphocytic Leukemia Cells. 
 
 
 
Peptides with high affinity to the B-cell receptor (BCR) fused to a toxin could be 
an effective therapy for Chronic Lymphocytic Leukemia (CLL) patients. We screened 
captured BCR of a CLL patient with peptides from 7 and 12-mer phage display libraries, 
using two strategies. Lymphocytes from two patients diagnosed with CLL expressing two 
different unmutated VH genes (VH 1-3 and VH4-34, respectively) were used. Membrane 
BCRs were obtained from patient CLL cells by lysis, identified by western blot, semi-
quantified and screened with phage libraries. The first strategy involved using patient 
VH4-34 BCRs which were captured using goat anti-human IgM to deplete bound phages. 
Unbound-phages were positively screened for those binding to patient VH 1-3 BCRs. 
Several clones were randomly selected and a sequence consisting of “LLPPAR_” peptide 
was found in both libraries. A phage clone displaying peptide “LLPPARE” was identified 
to bind to goat anti-human IgM. By including more goat anti-human IgM negative 
selections, we identified 3 different phages displaying peptides “GFTFMPA”, 
“QSRPLLP” and “GLPCCSS”. Clones “GFTFMPA” and “GLPCCSS” showed binding 
iv 
 
to goat anti-human IgM, while “QSRPLLP” did not. Phage clone “QSRPLLP” showed 
no binding to human serum IgM but showed binding to both patients’ BCRs. 
“QSRPLLP” peptide binds a common BCR molecule region present in both patients but 
not present in human serum IgM. This data suggests that it is possible to use a peptide-
phage display library to select peptides unique for the BCRs of CLL patients. However, 
the critical component in making this process patient-specific resides in enhanced 
discrimination in phage selection.   
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INTRODUCTION 
B-Cell Chronic Lymphocytic Leukemia (CLL) is the most common adult 
leukemia in Western countries [1]. Most patients are asymptomatic or present with 
reduced tolerance to exercise and fatigue, autoimmune hemolytic anemia, and sometimes 
with lymphoadenopathy. The laboratory diagnostic hallmark is the presence of small 
monoclonal lymphocytosis (greater than 5,000/μL) with infiltration into bone-marrow 
and secondary lymphoid organs [2]. CLL cells express CD5, CD19, CD23, and low 
levels of surface immunoglobulin and CD79b (the Ig-coreceptor) [3]. The increase in cell 
numbers over time is a dynamic process between cell proliferation and apoptosis[4]. CLL 
cells do not secrete antibodies, resulting in hypogammagobulinemia, which contributes to 
susceptibility to major infections and accounts for about 50% of deaths [5-7]. 
CLL has a heterogeneous clinical course [8] which can be divided into three 
phases [9]: low risk stage patients with little or no clinical disease, intermediate-risk 
stage, with a period of inactivity of the disease and longer survival time (24.4 years after 
diagnosis), and high-risk stage patients with an aggressive course resulting in a decrease 
in quality of life and early death (median 9.7 years after diagnosis) [10].  Clinical stage 
systems were developed to describe the disease progression [11, 12]. A higher stage 
indicates worse prognosis. 
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There is currently no cure for CLL. The treatment for cases with poor prognosis 
of CLL is the use of alkylating agents, purine analogs, and anti-CD20 and anti-CD52 
antibodies. The addition of humanized anti-CD52 or chimeric anti-CD20 to purine 
analogs showed a prolongation of progression free survival in relapsed or refractory 
patients [2]. These treatments can induce remission that can be consolidated in some 
cases with further therapy. The problems associated with these treatments are 1) 
increased immunosuppression causing an increase in major infections [13], and 2) 
selection of sub-clones with increased anti-apoptotic mutations [14]. In addition, the 
population with the more aggressive form of the disease will inevitably relapse in less 
than 4 years. Because of the adverse effects associated with therapy, physicians often use 
a “wait and see” strategy; follow the course of the disease, and treat patients at higher 
stages. Therefore, it is advised not to treat the patients in lower stages of the disease [15]. 
New therapies under investigation or entering clinical trials are also based on 
chemo- or immune-therapy but normal cells are also sensitive to these drugs [16]. Thus, 
these therapies are comparable to those currently in use in that they target an antigen 
shared by CLL and normal cells. 
In the last ten years the prognosis of the disease had been improved. Up-
regulation of molecules involved in activation such as CD38 [17]  or Zap 70 [18] are used 
as surrogates of replication [15]. High-level expression of these genes correlates well 
with high-risk CLL but are not helpful to assess the prognosis at early stages [19]. 
Deletions in chromosomes 17 and 11 correlate with poor prognosis and refraction 
to therapy, while deletions in chromosome 13 correlate with good prognosis [20]. Most 
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patients developing genetic abnormalities have been treated before, suggesting a selection 
of these clones due to treatment [14]. Nevertheless, a retrospective study of patients 
without previous therapy showed a clonal evolution to genetic abnormalities with poor 
prognosis [21]: patients with high Zap 70 expression of unmutated variable heavy chain 
gene (U-VH) evolved to chromosome deletion 17 and 11. Interestingly, patients with 
mutated variable heavy chain gene (M-VH) evolved to deletion 13 (good prognosis). 
The observation that some VH genes from CLL were unmutated while others 
were mutated [22] led to the study of the relation between mutated and non-mutated 
genes with the risk-level of CLL. Patients with less than 2% mutations in the VH (U-VH) 
are more likely to have a poor course of the disease compared to patients with more than 
2% mutations (M-VH) [23]. Recently, in a study of almost 2,000 patients, it was shown 
that patients with unmutated VH and usage of a particular set of D-genes are more prone 
to high-risk disease [24]. VH-mutation status is the only intrinsic prognostic factor 
independent of the disease stage. Patients with U-VH are at higher risk of a major 
infection and death by infections than patients with M-VH genes [6]. This is due to a 
deregulation associated with high numbers of CLL cells (almost 90% of circulating 
lymphocytes) and a dramatic decrease in number and function of T-cells and NK-cells 
[25]. 
In a recently published retrospective study it was shown that virtually all patients 
with monoclonal B-cell lymphocytosis that will become CLL already have the leukemic 
clones in circulation from 3-5 years before a clinical diagnosis of CLL [26]. However, 
only a small percentage of patients progress to CLL. The reason for disease progression 
is not understood. The etiology of this B-cell population and the mechanism leading to 
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this leukemia are also unknown. Until recently, this leukemia was considered an 
accumulation of small naïve lymphocytes with a defect in apoptosis [27], but the findings 
of hypermutated clones plus the combination of expression of cell markers led 
researchers to postulate that CLL derives from innate-like “antigen experienced” 
lymphocytes derived from the human counterpart of the murine “innate-like” B-cell 
populations [28]. Cross-reaction with auto-antigens, environmental antigens and/ or 
infection may play a role in selecting B-cell clones that will become neoplastic in CLL 
cells [24, 29, 30]. A recent study of the VH sequences of 1,577 patients showed that CLL 
display a restricted repertoire of Ig gene rearrangements, adding more evidence to antigen 
selection and induction in the development of CLL cells [3]. 
Clinical and experimental evidence strongly suggest that autoantigens are 
involved in the maintenance of activation of the cells originating CLL. Autoimmunity is a 
well-known complication of CLL [31-33]. The majority of CLL cells are kappa light 
chain restricted and 25% of these react to an anti-idiotype anti-kappa antibody [34, 35]. 
Naturally occurring CD5+ B-cells, with a restricted expression of VH genes, resembled 
auto-antibody producing CLL cells [36]. The study of the antibodies secreted by CLL 
cells after induction with phorbol myristate acetate (PMA) showed high degree of 
autoreactivity to self antigens such as IgG and single and double stranded DNA [37]. 
Mutated VH genes from CLL cells were reverted in vitro to the unmutated germline and 
showed reactivity to autoantigens [38]. Around 10% of CLL cells use VH gene 1-69, of 
which around 80% do not have mutations, and present stereotyped usage of CDR3s, 
indicating similar binding properties [39]. Hepatitis C virus drives the proliferation of 
“innate-like” B-cell clones using VH1-69 with polyreactive properties [40]. Using 
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molecular modeling of several CLL antibodies, it was shown that they might recognize 
the same antigen [41, 42]. Innate-like B-cells can receive help directly from dendritic 
cells [43] or from NKT-cells through the CD1 molecule [44] without need of T-cell help. 
Thus, it is becoming clear that innate-like B lymphocytes are activated by an 
environmental agent (e.g. viral infection) and continue proliferating by engaging 
autoantigens through their B-cell receptors (BCRs). Those CLL cells that do not mutate 
their VH might receive more stimulation by autoantigens, and thus have higher 
proliferation rate, which increases the risk for poor prognosis. The combined results 
suggest that the BCR is a possible therapeutic target against CLL. 
The BCRs are transmembrane proteins located on the outer surface of a B-cell 
and are involved in antigen recognition. BCRs are tetramers made of two heavy and two 
light chains. The light chain consists of two domains, the constant and variable domains. 
Each heavy chain consists of four constant and one variable domains in the IgM isotype 
and three constant and one variable domain in the IgD isotypes. Both isotypes are 
expressed on the cell membrane of a B cell carrying the same heavy and light variable 
domains with either IgM or IgD constant regions.  Each BCR has two antigen binding 
sites formed by the hypervariable regions of the variable heavy (VH) and variable light 
chains (VL).  After the B cell is activated, it differentiates into a plasma cell and the BCR 
is secreted as an IgM antibody. Indeed, the BCR of CLL cells was targeted in the past. 
Anti-idiotype antibodies were popular and used often in the 1980s. For example, an anti-
idiotype vaccine was developed against Hepatitis B [45]. Anti-idiotype antibodies were 
used as therapy against CLL cells [46, 47] . A partial remission was reported in a patient 
receiving therapy for one year, however, subsequent resistance to therapy occurred [48]. 
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Based on the published data, it is not clear whether the resistance was due to antigen 
modulation of the idiotype on the BCR or an immune response against the anti-idiotype 
(a mouse antibody). These antibodies were not conjugated to toxins or radionuclides, 
which suggests that the mechanism of clearance of the CLL cells was immune-mediated. 
New technologies allow for the successful use of variable fragments (Fv) of antibodies 
conjugated to toxins against molecules on the cell membrane of leukemias and 
lymphomas [49]. 
Anti-idiotype therapy is not currently used because the technique to produce and 
screen anti-idiotype antibodies is laborious, and the target for the anti-idiotype antibody 
was not well characterized, the anti-mouse response was problematic, and the role of the 
network of anti-idiotype-idiotype complexes was not defined. 
Another strategy to target the BCR of CLL cells is to discover ligands with high 
affinity to the BCR. For example, a powerful technique was developed by Dr. G. Smith’s 
lab at U. of Missouri using peptides displayed on M13 bacteriophages and encoded in the 
phagemids [50]. Many peptides obtained with phage display technology are used in 
imaging and as prospective for anti-cancer applications [51]. This strategy also has 
application for targeting BCRs of CLL cells. These authors selected nine-mer peptides 
specific to the BCR of CLL cells from a patient. Using flow cytometry, they demonstrate 
that these phages bound to the patient’s CLL cells with intensities more than 10 times 
higher compared to phage binding to CLL cells from other patients. The authors of this 
work did not characterize the VH usage of the patients, the binding affinities of the 
peptides to the BCR, the binding capabilities of the peptides against normal B-cells, nor 
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the CLL cell killing properties of the peptide [52]. However, this preliminary work shows 
that it is possible to select for peptides with specificity to the BCR of CLL cells. 
Based on new research demonstrating that unmutated VHs BCRs use similar 
rearrangements which seem to recognize the same antigens, and prior work indicating 
that BCRs can be used as a target for therapy, we targeted the BCRs of CLL cells with 
unmutated VHs using peptides mimicking the antigen binding to the binding pocket. By 
screening a second phage display library around the motif found in the first selection, this 
process resembles the mechanism of affinity maturation occurring with BCRs in the 
germinal center, but in this case, we selected peptides with the highest affinity for the 
BCR of the CLL cells. 
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HYPOTHESIS: 
Using a 7-mer or 12-mer Phage Display Peptide Library, it is possible to obtain peptides 
binding specifically to the binding pocket of B-cell receptor of CLL. 
RATIONALE AND SIGNIFICANCE OF STUDY 
The approach of targeting the BCR has the great advantage of low toxicity 
because only the CLL cells are marked for destruction. On the other hand, this strategy 
cannot be used as a generic therapy since BCRs differ from one CLL patient to the other. 
Until recently, the policy of the pharmaceutical industry was to have one medicine per 
disease; however clinical evidence, corroborated by genetic evidence indicated that this 
strategy is not optimum. Thus, the strategy of “one fits all” is under scrutiny by the 
scientific community and the pharmaceutical industry [53, 54], as the ability to genotype 
patients has become common and provides a basis for individualized therapy [55]. At this 
time, it is not advised to make therapeutic decisions based on the rate of VH mutation 
because of the drawbacks of the current therapy [2]. A therapy specifically targeting the 
CLL cell with low toxicity could be used soon after diagnosis with CLL patients with 
poor prognosis, and will have a significant social impact on many patients with CLL 
before progression to higher stages. 
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CHAPTER 1: Characterization of cells from CLL patients 
1.1 Materials /Methods: 
Subjects 
Peripheral blood sample from healthy subjects and two untreated individuals 
diagnosed with CLL were investigated in this study. In all cases, patients provided 
informed consent for use of peripheral blood in this investigation.  
Peripheral blood mononuclear cells isolation 
Peripheral blood from CLL patients and healthy subjects was obtained using 
EDTA tubes and stored at 4
0
C. In a biosafety cabinet, the patient blood was diluted 1:2 
with 2mM EDTA in HBSS pH 7.4 in a sterile 15 mL conical tube. Six milliliters of 
diluted blood was gently layered on top of 2 mL Histopaque 1077 (Sigma-Aldrich). Each 
15 mL conical tube was then centrifuged (with centrifuge brake switched “OFF”) at 2000 
RPM for 20 minutes at room temperature. The peripheral blood mononuclear cell 
(PBMC) buffy coat layer was collected using a Pasteur pipette, and added to cold 10 mL 
1% BSA, 2mM EDTA in HBSS pH 7.4. The cells were washed 3X with 10 mL 1% BSA, 
2mM EDTA in HBSS pH 7.4 at 1000 RPM for 5 minutes. After the final rinse, the cells 
were resuspended in 5 mL 1% BSA, 2mM EDTA in HBSS pH 7.4 and counted. For cell 
quantification, 10 microliters of cell suspension was added to 80 microliters of HBSS pH 
7.4 and an additional 10 microliters of trypan blue (Invitrogen 
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Cat. No 15250-061) was added to give a 1:10 dilution. Cells were quantified using a 
hemocytometer and a light microscope [56]: 
Cryo-preservation of isolated PBMCs from CLL patients 
CLL peripheral blood mononuclear cells were frozen in 1.5 mL cryovials at a 
concentration of 1-2 x 10
7
 cells per vial in 2% DMSO, 10% FCS in RPMI. Cryovials 
were stored at -70
0
 C overnight and then transferred to liquid nitrogen. 
Freezing of CLL cells in Tri-Reagent 
Obtained CLL PBMCs were pelleted at 800 xg and resuspended in TE pH 8.0 
(IDTE lot no. 11-05-01-10) to a concentration of 5x10
6 
cells per 250 microliters. The cell 
suspension, 250 microliters, was aliquoted into 1.5 mL cryovials followed by addition of 
750 microliters of Tri Reagent (Molecular Research Center, Inc. Cat No. TR118). Tryzol 
samples were kept frozen at -70
0
C. 
RNA isolation from PBMCs 
Frozen 1.5 mL cryovial Tryzol sample was quickly thawed and incubated at room 
temperature for 5 minutes. After 5 minutes incubation, 1 mL Tryzol sample was 
transferred into a 1.5 mL microcentrifuge tube with the addition of 250 microliters of 
chloroform. Tube was capped and vigorously shaken for 15 seconds and incubated for 5 
minutes at room temperature. Sample was then centrifuged at 12000 RPM for 15 minutes 
at 4
0
C. Using RNase-free tips, the upper aqueous layer was carefully transferred into a 
newly labeled 1.5 mL microcentrifuge tube containing 700 microliters of isopropanol and 
incubated for 10 minutes at room temperature. After 10 minutes of incubation, the sample 
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was centrifuged at 12000 RPM to pellet RNA. Pelleted RNA was washed with 750 
microliters of 75% ice-cold ethanol at 7500 RPM for 5 minutes at 4
0
. RNA pellet was air-
dried and dissolved in 20 microliters of RNase-free water (GIBCO ultra pure) containing 
1 microliter of rRNasin (Promega N251A). RNA concentration was determined using a 
spectrophotometer (Jenway Genova) at excitation wavelengths of 260 nm / 280 nm. RNA 
concentration was calculated using the formula below[56]: 
[RNA] =   Reading at 260 nm x dilution factor x 40 micrograms/ microliter 
Reverse-transcription on RNA from patients “P” and “E” 
RT-PCR tube was loaded with 3 micrograms of RNA, 1 microliter 7.5 
micromolar IgM 342-356 reverse primer (Table 1a), 4 microliters of 2mM dNTPs (NEB 
# N0447S) and DNase/ RNase-free distilled water (GIBCO Ultra pure),  to bring to a 
final volume of 16 microliters. Tube was incubated at 65
0
C for 5 minutes, placed on ice 
for 2 minutes and briefly centrifuged for 5 seconds. After centrifugation, tube received 1 
microliter rRNasin (Promega N251A), 2 microliters M-MuLV Transcriptase Reaction 
buffer (M-MuLV 10X buffer, NEB Cat. No. B0253S) and 1 microliter M-MuLV Reverse 
transcriptase (RT-M-MuLV, NEB Cat. No. M0253S). Tube was incubated at 42
0
C for 60 
minutes and then incubated at 65
0
C for 20 minutes. Obtained cDNA was stored at -20
0
C. 
PCR on cDNA from patients “P” and “E” using Variable Heavy chain primers 
Five PCR tubes were labeled P-1-M, P-2-M, E-1-M, E-2-M and Control. Each 
PCR tube received 22 microliters of DNase/ RNase-free distilled water (GIBCO Ultra 
pure), 5 microliters of VentR (10x) ThermoPol Reaction buffer (NEB Cat. No. B9004S, 
lot No. 0010906), 5 microliters of 2mM dNTPs (NEB Cat. No. N0447 S) and 3 
 
12 
 
microliters of 15 mM IgM 336-356 primer (Table 1b). Tubes P-1-M, E-1-M and Control 
each received 9 microliters of “primer cocktail 1”containing 3 microliters of each of the 
following primers: VH1FR1, VH2FR1, and VH3FR1 (Table 1c). Tubes P-2-M and E-2-M 
each received 9 microliters of “primer cocktail 2”containing 3 microliters of each of the 
following primers: VH4FR1, VH5FR1, and VH6FR1
 
(Table 1c). Tubes P-1-M and P-2-M 
received 5 microliters of cDNA from patient “P”, while tubes E-1-M and E-2-M received 
cDNA from Patient “E”. The samples were heated for 2 minutes at 94
0
C in a PCR cycler 
(Labnet Multi Gene II) and immediately place on ice for 2 minutes and briefly 
centrifuged for 5 seconds. Each tube, including the Control tube received 1 microliter of 
VentR DNA Polymerase M0254S (NEB lot No. 0310906). PCR tubes were run in a PCR 
cycler (Labnet Multi Gene II) for 35 cycles with a 45 second denaturation at 94
0
C, 45 
second annealing at 60
0
C, and 1 minute extension at 72 
0
C. 
Table 1a. IgM Reverse primer used in reverse transcription for cDNA production 
Reverse Primer Primer sequence   
IgM-REV 342-356 5’-CAG GAC AAA GTG ATG-3’   
 
Table 1b. IgM Reverse primer sequence for sequencing of PCR products 
Reverse Primer Primer sequence 
IgM-REV 336-356 5’-CAG GAC AAA GTG ATG GAG TCG-3’ 
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Table 1c. Primer sequences for variable heavy chain gene families 
IGH Primer sequence 
VH1FR1 (1-2) (-252) 5’- GGCCTCAGTGAAGGTCTCCTGCAAG- 3’ 
VH2FR1 (2-5) (-284) 5’- GTCTGGTCCTACGCTGGTGAAACCC- 3’ 
VH3FR1 (3-7) (-256) 5’- CTGGGGGGTCCCTGAGACTCTCCTG- 3’ 
VH4FR1 (4-4) (-256) 5’- CTTCGGAGACCCTGTCCCTCACCTG- 3’ 
VH5FR1 (5-51) (-255) 5’- CGGGGAGTCTCTGAAGATCTCCTGT- 3’ 
VH6FR1 (6-1) (-263) 5’- TCGCAGACCCTCTCACTCACCTGTG- 3’ 
 
Electrophoresis of Variable Heavy chain VH FR1 PCR products 
Ten microliters of each PCR product (P-1-M, P-2-M, E-1-M, E-2-M and Control) 
was added to 2 microliters of Loading Dye (NEB Cat. No B7021S) and separated using a 
1.8% Agarose gel (Nusieve 3:1 Agarose) in 40 ml of TBE (GIBCO BRL Ultra Pure Cat 
No. 15546-013) with 2 microliters of Ethidium Bromide in TBE at 90 mV. Seven 
microliters of 100bp DNA ladder (Promega Cat. No. G210A) was added to 3 microliters 
of TE pH 8.0 (IDTE lot no. 11-05-01-10) and 2 microliters of Loading Dye (NEB Cat. 
No B7021S) and run along the PCR samples. DNA fragments of approximately 500bp 
were excised from the agarose gel and extracted using GeneJET 
TM
 gel extraction kit 
(Fermentas Cat. No. K0691, Lot No. 00057032) and each resuspended in 50 microliters 
 
14 
 
of Elution Buffer. Each extracted DNA fragment was added to reverse primer IgM 336-
356 for sequencing at Retrogen, Inc (San Diego, CA). 
Flow cytometry 
Isolated PBMCs from healthy donor, CLL patients “E” and “P” were divided into 
1.5 ml microcentrifuge tubes, with a total amount of 1 x 10
5
 cells used per reaction tube,  
for subsequent staining with fluorophore conjugated antibodies. The cells were pelleted at 
2000RPM for 5 minutes at 4
0
C and resuspended in 100 microliters of one of the 
following antibody dilution cocktails in HBSS 1%BSA, 2mM EDTA: Group 1 cocktail 
of anti-CD19 APC, anti-CD5 PE-Cy7, anti-Lambda PE, anti-Kappa FITC. Group 2 
coctail of anti-CD19 APC, anti-CD5 PE-Cy7 and anti-IgM biotin with streptavidin  
FITC. Group 3 cocktail of mouse IgG isotype controls. The cells were incubated in the 
dark on ice for 30 minutes with gentle agitation every 10 minutes. After a 30 minute 
incubation period, each sample was washed 3 times with 500 microliters of HBSS 
1%BSA, 2mM EDTA.  After the final rinse, each cell pellet was resuspended in 200 
microliters of HBSS containing 1% paraformaldehyde and stored at 4
0
C in darkness. 
Samples were run on an Accuri-C6 flow cytometer and analyzed  using Accuri C-6 
CFLOW PLUS software. 
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1.2 Results: 
Peripheral blood mononuclear cells isolation and RT-PCR analysis on CLL cells 
mRNA 
Peripheral blood mononuclear cells were isolated from a healthy volunteer, CLL 
patients “E” and “P” by density gradient centrifugation as shown in Figure 1.  
 
Figure 1. PBMCs separation from CLL patient “P” and healthy volunteer 
peripheral blood, using Histopaque 1077. 
As shown in Table 2, CLL patients “P” and “E” total cell counts were greater than 
5 x 10
6
 PBMCs per milliliter. Patient “P” had 1.5 x 10
8
 PBMC per milliliter of blood, 
while highest count for CLL patient “E” was 3.3 x 10
7
 cells per milliliter of blood. 
Table 2. PBMC counts of healthy volunteer, CLL patients “P” and “E”. 
Patient PBMCs per mL of Blood (x10
7
 cells) 
Healthy donor 0.5 
 
 
Patient “P” 15 
  
Patient “E” 
3.3 
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RT-PCR on RNA isolated from CLL PBMCs 
Frozen 1.5 ml cryovial Tryzol samples from CLL patients “E” and “P” were 
quickly thawed and incubated at room temperature for 5 minutes.  RT-PCR was 
performed on CLL patients “E” and “P” Tryzol samples (Figure 2), using the procedure 
in “Materials and Methods” and reverse-transcribed using IgM 342-356 reverse primer 
(Table 1a). Obtained cDNA from patients “P” and “E” were PCR-amplified using 
Variable Heavy Chain Forward primers (Table 1c) and IgM 336-356 reverse primer 
(Table 1b).  
 
 
Figure 2. Schematic Representation of RT-PCR Amplification of cDNA using 
Variable Heavy Chain Framework 1 (VH FR) Gene Primers. 
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Using a 1.8% Agarose gel (Nusieve 3:1 Agarose), the CLL patients Variable 
Heavy Chain PCR products were separated (Figure 3), excised, extracted and purified 
using GeneJET 
TM
 gel extraction kit (Fermentas Cat. No. K0691, Lot No. 00057032).  
 
Figure 3. DNA Gel Electrophoresis of RT-PCR IGH Gene Products. VH1FR1 (1-2) (-
252), VH2FR1 (2-5) (-284), VH3FR1 (3-7) (-256), VH4FR1 (4-4) (-256), VH5FR1 (5-51) (-
255), VH6FR1 (6-1) (-263) primers and IgM-REV 336-356 primers were used the the RT-
PCR. Notation: “E-1-M” (CLL Patient “E”-Primer set 1- Reverse Primer IgM 336). 
Each extracted DNA fragment was added to reverse primer IgM 336-356 and sent 
for sequencing at Retrogen, Inc (San Diego, CA). Analysis showed CLL Patient “P” used 
VH 1-3
*
01with no mutations (100 percent identical), D2-2
*
01 with 3 mutations out of 12 
nucleotides and JH4-02
*
01 with no mutations (100 percent identical) (Figure 4).  
Analysis of Variable Light Chain showed that CLL patient “P” used VK1-39
*
01 with no 
mutations (100 percent identical) and JK1
*
01. CLL patient “E” used VH4-34
*
01 with 2 
mutations out of 285 nucleotides (99.30 percent identical), a possible D2-2
*
01 with 4 
mutations out of 16 nucleotides and JH6-02
*
01 with 1 mutation out of 58 nucleotides 
(Figure 5). Analysis of Variable Light Chain showed that CLL patient “E” used a 
VK5
*
02. 
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Patient “P” 
 
 
 
 
Figure 4. Variable Heavy and Light Chains Sequence Analysis of CLL Patient “P”. 
RT-PCR products were sequenced and the germline usage was analyzed. 
  
 FR1  
 1                       CDR1 
 Q  V  Q  L  V  Q  S  G  A  E  V  K  K  P  G  A  S  V  K  V  S  C  K  A  S  G  Y  T  F  T     
CAGGTCCAGCTTGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCTTCTGGATACACCTTCACT 
 
       FR2            CDR2     FR3 
          39                                                     66 
 S  Y  A  M  H  W  V  R  Q  A  P  G  Q  R  L  E  W  M  G  W  I  N  A  G  N  G  N  T  K  Y  S     
AGCTATGCTATGCATTGGGTGCGCCAGGCCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAATATTCA 
 
       74 
 Q  K  F  Q  G  R  V  T  I  T  R  D  T  S  A  S  T  A  Y  M  E  L  S  S  L  R  S  E  D  T  A     
CAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCT 
 
          104 
 V  Y  Y  C   
GTGTATTACTGT 
 
 CDR3 
           106        P  N1            D2-2*1                  N2 JH4-02    118           128 
  A  R   D  Q  W  L  P  I  T  T  L  D  Y   W   G   Q   G   T   L   V   T   V   S   S  
 GCGAGA GATCAGTGGTTACCAATTACTACCCTTGACTAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA 
 ...... ..        .....GC.G...   ........ ... ... ... ... ... ... ... ... ... ... ... 
 
 
VH (X62109) IGH V1-3*01 O mutations (100 % identity) 
D D2-2*01 3 mutations in 12 nucleotides 
J JH4-02*01 0 mutations 100% identity 
Kappa Patient-P 
 
Patient-P   D  I  Q  M  T  Q  S  P  S  S  L  S  A  S  V  G  D  R  V  T  I  T  C  R  A  
           GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCA 
 
Patient-P   S  Q  S  I  S  S  Y  L  N  W  Y  Q  Q  K  P  G  K  A  P  K  L  L  I  Y  A   
           AGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCT 
 
Patient-P   A  S  S  L  Q  S  G  V  P  S  R  F  S  G  S  G  S  G  T  D  F  T  L  T  I   
           GCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATC 
 
Patient-P   S  S  L  Q  P  E  D  F  A  T  Y  Y  C  Q  Q  S  Y  S  T  P  P  W  T  F  G    
           AGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTCCGTGGACGTTCGGC 
 
Patient-P   Q  G  T  K  V  E  I  K   
           CAAGGGACCAAGGTGGAAATCAAA 
 
 
Vkappa (X59315) IgKV1-39*01 100% identity 
Jkappa (J00242) JK1*01 
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Patient “E” 
 
 
 
 
Figure 5. Variable Heavy and Light Chains Sequence Analysis of CLL Patient “E”. 
RT-PCR products were sequenced and the germline usage was analyzed. 
    FR1 
Patient-E  Q  V  Q  L  Q  Q  W  G  A  G  L  L  K  P  S  E  T  L  S  L  T  C  A  V   
          CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTC 
VH4-34*01 ........................................................................ 
 
              CDR1        FR2 
Patient-E  Y  G  G  S  F  S  G  Y  Y  W  S  W  I  R  Q  P  P  G  K  G  L  E  W  I  G        
          TATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGTCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGG 
VH4-34*01 .........................................C................................. 
 
     CDR2     FR3 
Patient-E  E  I  N  H  S  G  S  T  N  Y  N  P  S  L  K  S  R  V  T  I  S  V  D  T  S   
          GAAATCAATCATAGTGGAAGCACCAACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCC 
VH4-34*01 ........................................................................... 
          
Patient-E  K  N  Q  F  S  L  N  L  S  S  V  T  A  A  D  T  A  V  Y  Y  C 
       AAGAACCAGTTCTCCCTGAATCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGT   
VH4-34*01 ....................G.......................................... 
         K  
 
           D2-2*01         JH6-02 
Patient-E  V  A  A  A  A  A  Y  Y  Y  Y  G  M  D  V  W  G  Q  G  T  T  V  T  V  S  S   
          GTAGCAGCAGCAGCGGCCTACTATTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA 
        ....T..T.C....T........C................................................... 
    
 
VH (ABO19439) IGHV4-34*01 2 mutations out of 285 nucleotides (99.30%) 
Possible D2-2*01   4 mutations out of 16 nucleotides 
JH JH6-02 1 mutation out of 58 nucleotides 
Kappa Patient-E 
 
 
PATIENT-E   E  T  T  L  T  Q  S  P  A  F  M  S  A  T  P  G  D  K  V  N  I  S  C  K  A 
           GAAACGACACTCACGCAGTCTCCAGCATTCATGTCAGCGACTCCAGGAGACAAAGTCAACATCTCCTGCAAAGCC 
 
PATIENT-E   S  Q  D  I  D  D  D  M  N  W  Y  Q  Q  K  P  G  E  A  A  I  F  I  I  Q  E    
           AGCCAAGACATTGATGATGATATGAACTGGTACCAACAGAAACCAGGAGAAGCTGCTATTTTCATTATTCAAGAA 
 
PATIENT-E   A  T  T  L  V  P  G  I  S  P  R  F  S  G  S  G  Y  G  T  D  F  T  L  T  I   
           GCTACTACTCTCGTTCCTGGAATCTCACCTCGATTCAGTGGCAGCGGGTATGGAACAGATTTTACCCTCACAATT 
 
PATIENT-E   N  N  I  E  S  E  D  A  A  Y  Y  F  C  L  Q  H  D  N  F  P   Q     T  F  G  Q   
           AATAACATAGAATCTGAGGATGCTGCATATTACTTCTGTCTACAACATGATAATTTCCCT CAAAG ACGTTCGGCCAA  
 
            G  T  K  V  E  I  K   
           GGGACCAAGGTGGAAATCAAA 
 
           P 
   Vkappa5-2*01  
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Flow cytometry analysis 
In order to characterize patients “E” and “P” B-cells, immunophenotying was 
performed on isloated PBMCs. Isolated PBMCs from a healthy donor, and cells from 
CLL patients “E” and “P” were stained with the following antibody dilution: Group 1 
cocktail of anti-human CD19 APC, anti-human CD5 PE-Cy7, anti-human lambda PE,and 
or anti-human kappa FITC, Group 2 cocktail of anti-human CD19 APC, anti-human CD5 
PE-Cy7 and anti-human IgM biotin with streptavidin  FITC, Group 3 cocktail of mouse 
IgG isotype controls, pelleted and resuspended in 200 microliters of HBSS containing 1% 
paraformaldehyde. 
Group 1 samples (mouse anti-human CD19 APC, CD5 PE-Cy7, lambda PE,and 
kappa FITC stained PBMCs) were then run on an Accuri-C6 flow cytometer and 
analyzed using Accuri C-6 CFLOW PLUS. As shown in Figure 6, by gating on the 
“lymphocyte” population within the healthy volunteer sample, the CD19 and CD5 
positive population within the “lymphocyte” gate was 5.5% with a kappa to lambda ratio 
of 3:2 (55.8% kappa positive to 39.2% lambda positive). 
By gating on the lymphocyte population within the sample, the percent of CD5
+
 
CD19 
+
 cells in patient “P” was 94.1% of which 89.9% of the cells were positive for 
kappa light chain (Figure 7). The CD5
+
 CD19 
+
 within patient “E” was 88.9% of which 
65.2% of the cells were positive for kappa light chain and 26.1% positive for Lambda 
light chain (Figure 8). 
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  A.                                                         B. 
 
C.                                                         D. 
 
Figure 6. Flow Cytometry Analysis of PBMCs from Healthy Donor Peripheral 
Blood. Cells were stained with anti-human CD19-APC, CD5 Pe-Cy7, anti-kappa FITC 
and  anti-lambda PE. A. Diagram shows the “lymphocyte” gate on a side scatter (SSC-H) 
versus forward scatter (FSC-H) plot. B. The diagram shows the CD19 positive B-cells 
(R1) on a density plot of CD5 Pe-Cy7 versus CD19-APC positive stained cells within 
“lymphocyte gate”. C. Graph shows a density plot of B-cells kappa light chain usage. D. 
Graph shows a density plot of B-cells lambda PE light chain usuage. 
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A.                           B. 
 
     C. 
 
Figure 7. Flow Cytometry Analysis of PBMCs from CLL Patient “P” Peripheral 
Blood. Cells from CLL patient were stained with anti-human CD19-APC, CD5 Pe-Cy7, 
anti-kappa FITC and anti-lambda PE. A. The diagram is the side scatter (SSC-A) versus 
forward scatter (FSC-A) plot with a lymphocyte gate. B. The diagram is a density plot of 
CD5 Pe-Cy7 versus CD19-APC positive stained cells gated on the “lymphocyte gate”.  
C. Diagram is a density plot showing analysis of CD19+/CD5+ cells from CLL patient 
light chain usage after staining with anti-kappa FITC and anti-lambda PE . 
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A.                                                             B. 
 
                      C. 
 
Figure 8. Flow Cytometry Analysis of PBMCs from CLL Patient “E” Peripheral 
Blood. Cells from CLL patient were stained with anti-human CD19-APC, CD5 Pe-Cy7, 
anti-kappa FITC and anti-lambda PE. A. Diagram is the side scatter (SSC-A) versus 
forward scatter (FSC-A) plot with a lymphocyte gate. B. The diagram is a density plot of 
CD5 Pe-Cy7 versus CD19-APC positive stained cells in a “lymphocyte gate”. C. 
Diagram is a density plot showing analysis of CD19+/CD5+ cells from CLL patient light 
chain usage after staining with anti-kappa FITC and anti-lambda PE. 
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To compare cell surface IgM expression on B-cells, Group 2 samples (mouse 
anti-human CD19 APC, CD5 PE-Cy7, IgM biotin with streptavidin  FITC stained 
PBMCs) were analyzed using Accuri C-6 CFLOW PLUS. As shown in Figure 9, healthy 
volunteer B-cells were identified by using CD19 from which marker “M1” (CD19 
positive population) was applied to the IgM plot to determine the mean IgM fluorescence 
intensity “M2”. Mean IgM fluorescence intensity “M2” of CLL cells in patients “E” and 
“P” was determined by gating on the “M3” ( CD5 positive cells) within “M1” (CD19 
positive cells) on the IgM histogram plot. The mean IgM fluorescence intensities for the 
healthy volunteer, and CLL patients “E” and “P” were “8.3 x 10
4
 ”, “9.8 x 10
4
” and “2.8 
x 10
4
”, respectively, indicating that CLL patient “P” had much lower expression of IgM 
on CD5
+
 CD19
+
 B-cells and probably at late stage CLL, while patient “E” IgM 
expression was similar to the healthy donor B-cells and is probably at early stage of the 
disease. 
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Figure 9. Flow CytometryAanalysis of Cell Surface IgM Expression on Healthy Donor B-cell and CLL Patients “P” and “E” 
B-cells. Peripheral blood PMBCs were stained with mouse anti- human CD19, CD5 and IgM antibodies. B-cells were identified using 
CD19 expression and CLL cells identified with co-expression of CD5 and CD19.  
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CHAPTER 2: Semi-quantification of isolated BCRs from patients 
2.1 Materials /Methods: 
Before patient BCRs could be targeted using the phage display library, the 
isolated PMBCs from each patient had to be lysed, using a mild detergent to release all 
surface proteins including the BCRs without denaturing them, and total protein 
concentration determined and patient BCRs semi-quantified, as explain below: 
Protein extraction from isolated CLL patient PBMCs 
Patient PBMCs, 2 x 10
7
 cells, were lysed overnight in 0.9 mL containing TBS, 
1% Tween-20, 10 μl of 0.5 M EDTA and 20 μl of HALT Protease Inhibitor Cocktail 
(Thermo Scientific, Cat. No. 78430, Lot No. KG134034). Tubes were centrifuged at 
14,000 RPM for 30 seconds, protein supernate transferred into microcentrifuge tubes and 
the pellet discarded. A solution was prepared with 4.5 mL of TBS plus 90 μl of HALT 
buffer and 45 μl of 0.5 M EDTA of which 0.9 mL of this solution was added to the 300 
μl of the protein supernatant and 250 μl aliquoted per tube and stored at -700C. 
Total protein quantification of CLL patient PBMC cell extracts 
Two hundred microliters of protein assay dye reagent concentrate (Bio-Rad, Cat. 
No.500-0006) was added to dilutions of known concentration of BSA standard to make 
the following final concentrations in dd: 0.5 μg/ ml, 1 μg/ ml, 2 μg/ ml, 5 μg/ ml, 7
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μg/ ml and 10 μg/ ml. Patient “P” and “E” samples were diluted in 0.8 ml distilled μl 
protein assay dye reagent concentrate. Two hundred microliters of dilutions were 
transferred into a well on a 96-well plate (Costar). The plate was read at 595 nm using 
Elx 800 biotek plate reader. A standard curve obtained from the BSA standard and the 
optical densities obtained for Patients “P” and “E” wells were used to extrapolate the 
concentrations of patients “P” and “E”.  
SDS-PAGE and western blot analysis of CLL patient protein lysates 
SDS-PAGE and Western blot analysis were then performed on patients “E” and 
“P” cell lysates, as mentioned below to determine if complete BCRs, based on size and 
staining with goat anti-human IgM, could be identified. In determining the presence of 
BCRs within cell lysates, 0.2 micrograms and 0.02 micrograms of each patient’s lysate, 
and standard human serum IgM were each diluted in a sample loading buffer containing 
β-mercaptoethanol and heated at 100 
0
C for 5 min prior to loading in a 15% Tris-HCl 
sodium dodecyl sulfate-polyacrylamide gel (Bio-Rad Criterion ™ Precast Gel, Cat# 345-
0019). The separated proteins were then transferred overnight onto an immuno-blot 
PVDF membrane (Bio-Rad Criterion Gel Blotting Sandwiches, Lot # BR7316003B). The 
membrane was blocked overnight with  PBS containing 1% non-fat milk, incubated with 
goat anti-human IgM perioxidase labeled (1:1000 dilution, Cat # 074-1003; KPL), 
incubated with Fluorescein (FITC) conjugated AffiniPure Rabbit Anti-goat antibody 
(1:500, Lot # 48485; Jaskson ImmunoResearch Lab, INC.). The bands were detected 
using anti-FITC alkaline phosphatase (1:1000 dilution) and an enhanced 
chemifluorescence (ECF) reagent before exposure to 473 nm laser using an Image Reader 
FLA-5100 Fuji Film Reader and image captured. 
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2.2 Results: 
Depletion and lysis of B cell-depleted PBMCs from a healthy donor 
B-cell depletion of a healthy donor PBMCs was performed by incubating with 
biotinylated mouse anti-human CD19 antibodies, washing, incubating with streptavidin-
coated magnetic beads and allowed to pass through a column which was attached to a 
magnet. CD19 positive B-cells remained attached to the column while the eluate was 
depleted of B-cells. Flow cytometery was performed on the PBMCs before and after 
magnetic bead separation by staining with mouse anti-human CD20 FITC and CD5 PE 
antibodies. To determine background binding pre-separated cells were incubated with 
anti-mouse IgG1 FITC and IgG1 PE antibodies. As shown in Figure 10 C and D, isolated 
PBMCs from the healthy volunteer was depleted of CD19 positive B-cells. Before B-cell 
depletion, CD20 positve B-cell count was 10.4% and after B-cell depletion, B-cell count 
reduced to 0.7%. B-cell depleted PBMCs were lysed as mentioned in “Materials and 
Methods”, and protein concentration determined to be 1.23µg/µl.  
To determine any non-specific binding from cell lysate non-BCR proteins, within 
the ELISA semi-quantification wells for patient BCRs, B-cell depleted PBMCs were 
lysed and spiked with known concentrations of human serum IgM. The B-cell depleted 
PBMC lysate, spiked with known concentrations of IgM, was used to, as a standard, 
generate a curve and compared to a standard curve which was obtained by not using B-
cell depleted PBMC lysate (Figure 13 B and C).
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A.                                                           B. 
 
C.         D. 
 
Figure 10. Depletion of CD19 Positive B-cells from PBMC of a Healthy Volunteer, 
using mouse anti-human CD19 magnetic bead-bound antibodies and stained with 
mouse anti-human CD20 PE and CD5 PECy7 antibodies. A. The “lymphocyte” gate 
on a side scatter (SSC-A) versus forward scatter (FSC-A) plot . B. A density plot of 
isotype controls, anti-mouse IgG1 FITC and IgG1 PE-Cy7 antibodies, used to determine 
non-specific binding. C. Shows CD20 versus CD5 Pe-Cy7 positive stained cells within 
“lymphocyte gate” before CD19 depletion. D. Shows CD20 versus CD5 Pe-Cy7 positive 
stained cells wihtin “lymphocyte gate” after CD19 depletion. R1 is the CD20 postive B-
Cells population. 
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Protein extraction and quantification of isolated CLL patient PBMCs 
CLL patient PBMCs were isolated, digested and total protein quantified against 
BSA standard (Figure 11) as described in “Materials and Methods”. CLL patient “P” 
protein concentration was calculated to be 1.78 μl/ μg, while protein concentration of 
CLL patient “E” was 1.96 μl/μg (Table 3). 
 
Figure 11. BSA Standard Line of Best-fit Graph. BSA standard was used for 
extrapolation of CLL patient total protein cell extracts concentration (R
2
 0.9889). 
 
Table 3. Total Protein Concentration within CLL Patient PBMC Lysate. 
Patient Protein concentration [µg/ µl] 
“P” 1.78 
“E” 1.96 
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SDS-PAGE and western blot analysis of CLL patient cell lysate 
In order to further determine the presence of IgM within the protein lysates, SDS-
PAGE and Western blotting, described in “Materials and Methods”, were performed on 
patient protein lysates and healthy donor lysate (B-cell depleted). Lysates were separated 
using a 15% Tris-HCl sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and 
transferred overnight onto an immuno-blot polyvinylidene difluoride membrane and IgM 
was detected using goat anti-human IgM antibody. Analysis of 0.2 μg and 0.02 μg of 
standardized IgM from human serum, patients “E” and “P” protein lysates showed a band 
at approximately 72 kDa showing the presence of IgM molecule and no band identified in 
healthy donor B-cell depleted PBMC cell lysate (Figure 12). 
 
Figure 12. Western Blot Analysis for IgM Detection within Protein Lysates of CLL 
cells from patients “E” and “P”. Western blot membrane showing distinct bands of 
IgM within IgM standard from human serum, CLL patients “P” and “E” PBMC lysates, 
and by staining with goat anti-human IgM antibody. Healthy donor B-cell depleted 
PBMC lysate showing no IgM band present. 
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BCR semi-quantification of isolated CLL patient PBMCs protein extracts 
As shown in Figure 13A, two 96-well ELISA plates (CLL patient “E” and “P” 
labeled plates) were sensitized with unconjugated goat anti-human IgM antibody, Fc 5µ 
fragment specific, in bicarbonate buffer.  
Each ELISA plate received 2-fold serial dilutions of lysate, obtained from PBMCs 
depleted of B-cells, but spiked with human serum IgM standard of known concentrations.  
IgM standard from serum was added to B-cell depleted PBMC healthy donor cell lysate 
before incubating with goat anti-human IgM to account for any non-specific binding due 
to other proteins within PBMC lysate. Two-fold serial dilutions of IgM from Human 
Serum (IgM standard) were also added to each plate in duplicates. Two-fold serial 
dilutions of patients “P” and “E” samples were tested in triplicates. 
The ELISA plates were read at 450 nm using a spectrophotometer and the 
absorbance recorded and plotted for each ELISA plate. As shown in Figure 13 B and C, 
absorbance values of CLL patient “E” dropped faster as compared to patient “P” lysate 
wells indicating a lower concentration of captured BCRs present within patient “E” 
PBMC lysate. 
Using each CLL patient’s plate “B cell-depleted lysate spiked with known 
concentrations of IgM from human serum”, standard curves with line of best fit were 
generated for each plate and used to determine IgM concentrations for patients “E” and 
“P” (Figure 14). BCR concentration in patients "E" and “P” lysate were determined, 
using the best-fit values from the standard curves, to be 0.048 μg/ µl and 0.180 μg/ µl, 
respectively (Table 4).  
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A.        
 
B. 
 
C. 
 
Figure 13. CLL Patients “E” and “P” cell lysate BCR Semi-Quantification. A. 
Schematic representation of method used to semi-quantify patient BCRs by extrapolating 
from a Human Serum IgM standard curve. B and C. Graphs showing the absorbance of 
serially diluted patient lysate, Standardized IgM and serial dilutions of Standardized IgM 
added to B cell-depleted PBMC lysate. 
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Figure 14.  Human Serum IgM Standard curves used to Semi-quantify 
concentrations of BCRs present in CLL Patients “P” and “E”cell lysates. Standard 
curves, for each CLL patient ELISA plate, obtained from B cell depleted-PBMC lysate 
spiked with known concentrations of Human Serum IgM (ng/ μl) and used to extrapolate 
CLL patients “E” and “P” BCR concentrations. Left panel: Graph of CLL patient “E” 
BCR standard quantification plate (R
2
 of 0.9718). Right panel: Graph of CLL patient “P” 
BCR standard quantification plate (R
2
 of 0.9784). 
 
 
Table 4. Semi-Quantification of BCRs in Patient "E" and “P” cell lysate. 
Patient Mean BCR concentration (μg/µl) 
"E" 0.048 
"P" 
0.180 
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Detection of kappa and lambda light chain in human serum IgM standard by 
capturing using goat anti-human kappa or lambda 
To determine the presence of kappa light chain on CLL patient BCRs within the 
cell lysates, two methods of detection (Figure 15 and 18) were optimized using human 
serum IgM Standard of known concentrations. As shown in Figure 15, ELISA plate was 
sensitized with goat anti-human kappa or goat anti-human lambda in 50 μl NaHCO3 pH 
8.6, for 1 hour at room temperature, washed and then blocked overnight at 4
0
C with 5% 
non-fat milk in PBS (0.1%Tween-20). Wells were then washed and incubated for 1hour 
with 2-fold serial dilutions of known concentrations of human IgM standard. All wells 
were washed and incubated for 1 hour at room temperature with horseradish peroxidase 
conjugated goat anti-human IgM. Wells were then washed, TMB substrate added and the 
reaction stopped with 1M sulfuric acid and read at 450nm. Absorbance versus IgM 
concentration curves were generated (Figure 16A and Figure 17A) from which lines of 
best-fit were obtained. Kappa and lambda detection assays had R
2
 values of 0.9333 and 
0.9224, respectively (Figure 16B and 17B). 
 
Figure 15. “Schematic Representation 1” of Human IgM Light Chain Detection. 
human IgM captured using goat anti-human kappa or lambda antibody and then detected 
using horseradish conjugated (HR) goat anti-human IgM. 
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 Line of best fit on selected region     Kappa light chain standard curve 
 
 
Figure 16. IgM Kappa Light Chain Detection in Human IgM from “Schematic Representation 1”. Human IgM was captured 
using goat anti-human kappa antibody (primary antibody) and anti-human IgM HRP conjugated used as secondary antibody. Left 
panel. The line of best fit used to estimate concentration of kappa light chain within Human IgM standard (R
2
 of 0.9333). Right panel. 
Absorbance values of kappa light chain detection from 2-fold serial dilutions of IgM (ng) from which linear slope section was taken. 
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Line of best fit on selected region      Lambda light chain standard curve 
 
Figure 17. IgM Lambda Light Chain Detection in Human IgM from “Schematic Representation 1”. Human IgM was captured 
using goat anti-human lambda antibody (primary antibody) and anti-human IgM HRP conjugate used as secondary antibody. Left 
panel. The line of best fit used to estimate concentration of kappa light chain within Human IgM standard (R
2
 of 0.9224). Right panel.  
Absorbance values of lambda light chain detection from 2-fold serial dilutions of IgM (ng) from which linear slope section was taken. 
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Detection of Kappa and Lambda Light Chain in Human Serum IgM Standard by 
capturing using goat anti-human IgM 
As shown in Figure 18, wells in an ELISA plate were sensitized with 0.5 μg goat 
anti-human IgM in 50 μl NaHCO3 pH 8.6 for 1 hour at room temperature, washed and 
then blocked overnight at 4
0
C with 5% non-fat milk in PBS (0.1%Tween-20). Wells were 
then washed and incubated for 1hour with 2-fold serial dilutions of known concentrations 
of human IgM standard for anti-kappa semi-quantification. All wells were washed, 
incubated for 1 hour at room temperature with either biotinylated mouse anti-human 
kappa antibody for kappa chain detection or with biotinylated mouse anti-human lambda 
antibody for lambda chain detection. All wells were then washed and incubated for 1 
hour at room temperature with streptavidin horseradish peroxidase. Wells were then 
washed and TMB substrate added, reaction stopped with 1 M sulfuric acid and read at 
450nm. Absorbance versus IgM concentration curves were generated (Figure 19A and 
20A) from which lines of best-fit were obtained. Kappa and lambda detection assays had 
R
2
 values of 0.9456 and 0.9946, respectively (Figure 19B and 20B). 
 
Figure 18. “Schematic Representation 2” of Human IgM Light Chain detection. 
Human IgM captured using goat anti-human IgM antibody and then light chain detected 
using mouse anti-human kappa or lambda IgM. 
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Line of best fit on selected region      Kappa light chain standard curve 
 
Figure 19. IgM Kappa Light Chain Detection in Human IgM from “Schematic Representation 2”. Human IgM was captured 
using goat anti-human IgM antibody (primary antibody) and biotinylated mouse anti-human kappa used as secondary antibody with 
SHRP. Left panel. The line of best fit used to estimate concentration of kappa light chain within Human IgM standard (R
2
 of 0.9456). 
Right Panel. Absorbance values of kappa light chain detection from 2-fold serial dilutions of IgM (ng) from which linear slope 
section was taken.
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Line of best fit on selected region      Lambda light chain standard curve 
 
Figure 20. IgM Lambda Light Chain Detection in Human IgM from “Schematic Representation 2”. Human IgM was captured 
using goat anti-human IgM antibody (primary antibody) and biotinylated mouse anti-human lambda used as secondary antibody with 
SHRP. Left panel. The line of best fit used to estimate concentration of lambda light chain within human IgM standard (R
2
 of 0.9946). 
Right panel. Absorbance values of lambda light chain detection from 2-fold serial dilutions of IgM (ng) from which linear slope 
section was taken. 
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IgM Kappa and Lambda Light Chain Detection within CLL Patient “P” and “E” 
cell lysate by capturing using goat anti-human IgM antibody 
After optimized methods were compared, and “Method 2” was used to semi-
quantify the light chain concentrations within CLL patients “P” and “E” cell lysates. 
“Method 2” was repeated using IgM standard, as shown in Figure 21.  The ELISA wells 
were sensitized with 0.5 μg goat anti-human IgM in 50 μl NaHCO3 pH 8.6, for 1 hour at 
room temperature, washed and then blocked overnight at 4
0
C with 5% non-fat milk in 
PBS (0.1%Tween-20). Wells were then washed and incubated with 2-fold serial dilutions 
of known concentrations of human IgM standard for anti-kappa semi-quantification. In 
parallel, goat anti-human IgM sensitized wells were also incubated, for 1 hour at room 
temperature, with 2-fold serial dilutions, starting with 2 μl, of CLL patients “E” and “P” 
lysates in blocking buffer. All wells were washed, incubated for 1 hour at room 
temperature with biotinylated mouse anti-human kappa antibody for kappa light chain 
detection. The ELISA to quantitate IgM lambda concentration within patient lystate was 
performed as described above except a biotinylated mouse anti-human lambda antibody 
was used for lambda light chain detection on IgM. All wells were then washed and 
incubated for 1 hour at room temperature with streptavidin horseradish peroxidase. Wells 
were then washed and TMB substrate added, reaction stopped with 1M sulfuric acid and 
read at 450nm. Absorbance versus IgM concentration curve was generated for kappa 
detection within IgM Standard (Figure 22A) from which a line of best-fit was obtained. 
Kappa light chain detection assay had an R
2
 value of 0.9650 (Figure 22B). The kappa 
light chain of CLL patients “P” and “E” were semi-quantified to be 4.81 μg/ μl and 2.11 
μg/ μl, respectively (Table 5). Absorbance versus IgM concentration curve was also 
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generated for lambda detection within IgM Standard (Figure 23A) from which a line of 
best-fit was obtained. Lambda light chain detection assay had an R
2
 value of 0.9909 
(Figure 23B). The lambda light chain within CLL patients “P” and “E” were semi-
quantified to be 0.06 μg/ μl and 0.56 μg/ μl, respectively. These results support the flow 
cytometry light chain analysis of CLL patients “P” and “E” with patient “E” having lower 
lambda positive CD5
+
/CD19
+
 population.  
Total protein concentrations within patient lysates, using "BSA" as standard, were 
1.78 μg/ μl and 1.96 μg/ μl for Patients “P” and “E”, respectively (Table 3). ELISA, using 
serum IgM as standard, by capturing patient IgM with goat anti-human IgM (Fc 5μ 
fragment specific) and then detecting with goat anti-human IgM (μ fragment specific) 
horseradish peroxidase labeled was 0.180 μg/ μl and 0.048 μg/ μl for patients “P” and 
“E”, respectively (Table 4). However, ELISA by capturing patient IgM with goat anti-
human IgM (Fc 5μ fragment specific) and then incubating with biotinylated mouse anti-
human kappa/lambda antibody yielded kappa concentration of 4.81 μg/ μl (+/- 0.54) and 
2.11 μg/ μl (+/- 0.35) for patients “P” and “E”, respectively. In addition, Lambda 
detection yielded 0.06 μg/ μl (+/- 0.05) and 0.56 μg/ μl (+/- 0.20) for patients “P” and 
“E”, respectively (Table 5 and 6). The higher concentrations observed of kappa and 
lambda between the ELISAs could be a result of repeated freeze thawing leading to a 
more concentrated cell lysate or much more efficient binding with the mouse anti kappa/ 
lambda antibodies. Despite the difference in concentrations between the ELISAs, it can 
still be concluded that patient “P” has all kappa, while patient “E” has both kappa and 
lambda, with kappa being more than lambda in patient “E” lysate. Also, Human IgM 
from Serum would have been a much better standard instead of BSA. 
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A.           B. 
                  
Figure 21. Schematic Representation of CLL Patients “P” and “E” BCR Light Chain detection. A. Human IgM captured using 
goat anti-human IgM antibody and then light chain detected using mouse anti-human Kappa or Lambda IgM antibody. B. CLL 
patients “P” and “E” BCRs were captured using goat anti-human IgM antibody (Model 2) and then light chain detected using mouse 
anti-human kappa or lambda IgM antibody.
. 
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Line of best fit on selected region      Kappa light chain standard curve 
 
Figure 22. IgM Kappa Light Chain in Human IgM for Semi-quantification of CLL Patients “P” and “E” BCR Concentration. 
Human IgM was captured using goat anti-human IgM antibody (primary antibody) and biotinylated mouse anti-human kappa used as 
secondary antibody with SHRP. Left panel. The line of best fit used to estimate concentration of kappa light chain within Human IgM 
standard (R
2
 of 0.9650). Right panel. Absorbance values of kappa light chain detection from 2-fold serial dilutions of IgM (ng) from 
which linear slope section was taken. 
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Line of best fit on selected region      Lambda light chain standard curve
 
Figure 23. IgM Lambda Light Chain in Human IgM for Semi-quantification of CLL Patients “P” and “E” BCR 
Concentration. Human IgM was captured using goat anti-human IgM antibody (primary antibody) and biotinylated mouse anti-
human lambda used as secondary antibody with SHRP. Left panel. The line of best fit used to estimate concentration of lambda light 
chain within Human IgM standard (R
2
 of 0.9909). Right panel. Absorbance values of lambda light chain detection from 2-fold serial 
dilutions of IgM (ng) from which linear slope section was taken. 
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Table 5. CLL patients Kappa light chain concentration determination using anti-human IgM to capture BCRs from Patient 
lysates (µg/µl). 
Patient Minimum Maximum Mean 
Std. Error 
(+/-) 
Lower 
95% CI of mean 
Upper 
95% CI of mean 
       
"P" 2.94 5.93 4.81 0.54 3.30 6.31 
"E" 1.43 2.98 2.11 0.35 0.99 3.23 
 
Table 6. CLL patients Lambda light chain concentration determination using anti-human IgM to capture BCRs from patient 
lysates (µg/µl). 
Patient Minimum Maximum Mean 
Std. Error 
(+/-) 
Lower 
95% CI of mean 
Upper 
95% CI of mean 
       
“P" 0.01 0.11 0.06 0.05 -0.56 0.69 
"E" 0.03 0.94 0.56 0.20 -0.06 1.18 
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CHAPTER 3: Use of 7-mer and 12-mer Phage Display Library to select peptides 
with high affinity to BCR isolates from CLL cells 
3 Materials / Methods: 
3.1 Can captured CLL patient BCRs withstand Phage Display Library surfacing 
panning conditions? 
A qualitative ELISA was performed to determine whether patient BCRs which 
were captured onto goat anti-human IgM sensitized well could withstand the surface 
panning conditions used in the selection process. Patients “E” and “P” wells were 
performed using 50 μl and 200 μl, respectively. The volumes were used because, in the 
phage selection process, 50 μl of Patient “E” unbound phages are transferred into Patient 
“P” well and the empty patient “E” wells are rinsed 3 times with 50 μl each wash and 
then transferred into Patient “P” well giving a total volume of 200 μl in Patient “P” well. 
As shown in Figure 24, wells “A” and “B” were sensitized with 1.6 micrograms of goat 
anti-human IgM in 50 μl of 0.1M NaHCO3 pH 8.6 solution. Well “C” was sensitized with 
1.6 micrograms of goat anti-human IgM in 200 μl of 0.1M NaHCO3 pH 8.6 solution. The 
plate was incubated for 1 hour at room temperature and then wells “A” and “B” were 
washed 3 times with 50 μl per wash of 0.05% Tween-20 in TBS, while well “C” was 
washed 3 times with 200 μl per wash of 0.05% Tween-20 in TBS. Wells A,“B”, “C”, 
“D”, and “E” were then blocked with 300 μl of 5% BSA in 0.1M NaHCO3 pH 8.6, 
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covered and incubated overnight at 4
0
C. After overnight blocking with 5% BSA in 0.1M 
NaHCO3 pH 8.6, the wells “A” and “B” were washed 3 times with 50 μl per wash of 
0.05% Tween-20 in TBS, while well “C” was washed 3 times with 200 μl per wash of 
0.05% Tween-20 in TBS. As a positive control, 100 μl (0.08 micrograms) of IgM from 
human serum was added to well “A” and incubated for 1 hour at room temperature. 
Twenty microliters of patient “E” lysate was added to 80 μl of 0.1M NaHCO3 pH 8.6 and 
50 μl of this was added to wells “B” and “D” and incubated for 1 hour at room 
temperature. Eight microliters of patient “P” lysate was added to 320 μl of 0.1M NaHCO3 
pH 8.6 and then 200 μl of this was added to wells “C” and “E” and incubated for 1 hour 
at room temperature. After 1 hour incubation, the well “A” was washed 3 times with 100 
μl per wash of 0.05% Tween-20 in TBS. Wells “B” and “D’ were washed 3 times with 50 
μl per wash of 0.05% Tween-20 in TBS, while wells “C” and “E” were washed 3 times 
with 200 μl per wash of 0.05% Tween-20 in TBS. Then the well “A” was washed 3 times 
with 100 μl per wash of TBS. Wells “B” and “D” were washed 3 times with 50 μl per 
wash of TBS, while wells “C” and “E” were washed 3 times with 200 μl per wash of 
TBS. 50 μl of 1:1000 dilution of peroxidase-labeled affinity purified goat anti-human 
IgM (µ) antibody (KPL Cat No. 074-10003) in 5% BSA in 0.1M NaHCO3 pH 8.6 was 
added to all the wells (“A”, “B”, “C”, “D” and “E”) and incubated for 1 hour at room 
temperature. The wells were then rinsed 3 times with 300 μl per wash of 0.05% Tween-
20 in TBS and rinsed again with 300 μl of TBS. The plate was allowed to incubate for 
about 10 minutes at room temperature and the reaction stopped with 50 μl of 1M H2SO4 
and a picture of the wells taken with a digital camera.  
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A. 
 
B.        C.       D.         E.  
 
Figure 24. Schematic Representation of ELISA Performed to Determine Whether Patient BCRs Captured Onto Goat Anti-
Human IgM Sensitized Well Could Withstand the Surface Panning Conditions Used in the Phage Display Library Selection 
Process.
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3.2 Strategy 1: 7-mer and 12-mer First Round Panning on CLL Patient BCRs 
As illustrated in Figure 26 and detailed below, in separate wells, BCRs from CLL 
patients “P” and “E” were captured using goat anti-human IgM. Patient “E” BCR-
captured well was used as the “Negative” subtraction plate to remove, from the Phage 
Display Peptide Library, phages binding to regions of the B-cell receptor. Since BCRs 
from patients “E” and “P” differed in the binding pocket, the remaining phages were 
incubated with the “Positive” selection patient “P” BCR-captured well. The unbound 
phages were discarded by washing 10 times with TBS (0.05% Tween). Patient “P” BCR-
bound phages, targeting the binding pocket, were eluted and amplified and the panning 
repeated with amplified phages. 
3.2.1 Sensitization of wells with anti-human IgM for “Negative subtraction” and 
“Positive Selection” plate 
Goat anti-human IgM, 1.6 µg in 50 µl 0.1M sodium bicarbonate pH 8.6 (Pierce 
lot # KH1248781), was added to sensitize the “Negative subtraction” wells on a 96-well 
plate. Incubated for 1 hour at room temperature and then washed 3 times with 50 µl per 
wash of 0.05% Tween-20 in TBS and then 3 times with 50 µl of TBS. “Positive 
selection” wells on the plate were sensitized with the 200 µl (1.6 µg) of goat anti human 
IgM. Incubated for 1 hour at room temperature, washed 3 times with 200 µl per wash of 
0.05% Tween-20 in TBS. and then washed 3 times with 200 µl per wash of TBS. The 
plates were then blocked with 300 µl of 5% BSA in 0.1M NaHCO3 pH 8.6, covered and 
incubated overnight at 4
0
C. 
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3.2.2 Capturing of patient “E” BCRs on “Negative subtraction” plate 
After overnight blocking with 5% BSA in 0.1M NaHCO3 pH 8.6, the “Negative 
subtraction” plates were washed 3 times with 50 µl per wash of 0.05% Tween-20 in TBS. 
The plates were then washed 3 times with 50 µl of TBS. Twenty microliters of patient 
“E” lysate was added to 80 µl of 0.1M NaHCO3 pH 8.6 and 50 µl of this was added to 
each goat anti-human IgM sensitized well on the “Negative subtraction” plate and 
incubated for 1 hour at room temperature. After 1 hour incubation, wells were washed 3 
times with 50 µl per wash of 0.05% Tween-20 in TBS. Plates were then washed 3 times 
with 50 µl of TBS. 
3.2.3 Capturing patient “P” BCRs on “Positive selection” plate 
After overnight blocking with 5% BSA in 0.1M NaHCO3 pH 8.6, the “Positive 
selection” plates were washed 3 times with 200 µl per wash of 0.05% Tween-20 in TBS 
and then washed 3 times with 200 µl of TBS. Eighty microliters of patient “P” lysate was 
added to 320 µl of 0.1M NaHCO3 pH 8.6 and then 200 µl of this was added to each goat 
anti-human IgM sensitized well on the “Positive selection” plate and incubated for 1 hour 
at room temperature. After 1 hour incubation, wells were washed 3 times with 200 µl per 
wash of 0.05% Tween-20 in TBS and then washed 3 times with 200 µl of TBS. 
3.2.4 Phage Display Library (7 and 12-mer) incubation in “Negative subtraction” plate 
Ten microliters of 7-mer Phage Display Library (E8100S, lot No. 0100908) or 12-
mer (E8110S, Lot No. 0170909) Phage Display Peptide library was added to 40 µl of 
0.05% Tween-20 in TBS. Diluted 7-mer or 12-mer Phage Display Peptide library was 
added to the “Negative subtraction” plate well and incubated at room temperature for 1 
 
52 
 
hour on a rocking plate. After 1 hour incubation, the plate was inclined and the 50 µl of 
unbound phages within the well were transferred into a microcentrifuge tube. The well 
was washed 3 times with 50 µl of 0.05% Tween-20 in TBS and the washes were added to 
the initial 50 µl of subtracted unbound phages to give a final volume of 200 µl. Five 
microliters of the subtracted unbound phages was kept for titration (P7R1-IN and P12R1-
IN) and the remaining 195µl “Subtracted 7 and 12-mer phage display libraries” was kept 
for “Positive selection” plate. 
3.2.5 Subtracted P7R1-IN and P12R1-IN incubation in “Positive selection” plate 
One hundred and ninety five microliters of “Subtracted Phage Display Peptide 
library” (P7R1-IN or P12R1-IN) library was added to the “Positive selection” well and 
incubated for 1 hour at room temperature on a rocking plate. After 1 hour incubation, the 
non-binding phages were rinsed off by emptying the wells and then tapping the plate onto 
paper towels. The well was washed 10 times with 200 μl of 0.05% Tween-20 in TBS per 
wash. The bound phages remaining in the well were eluted with 15 minutes gentle 
rocking with 200 μl of elution buffer (0.2 M Glycine, HCl pH 2.2, 1% BSA).  After 15 
minute incubation with the elution buffer, the 200 μl of eluted phages were transferred 
into a 1.5mL microcentrifuge tube containing 30 μl of 1M Tris-HCl pH 9.1. After 
neutralization, 5 μl of the eluate was kept for titration (P7R1-OUT and P12R1-OUT) and 
remaining 225 μl was amplified by incubating all the eluate in 4 ml of E. coli ER2738 in 
log phase  (O.D. of 0.05) within a 50 ml Erlenmeyer flask for 4.5 hours at 37
0
C in a 
shaker at 260 RPM. 
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3.2.6 Amplification of eluted 7 and 12-mer first round phages 
After 4.5 hour incubation, the 4 mL of the amplified product was aliquoted into 
1.5 mL microcentrifuge tubes and centrifuges at 12000 RPM for 10 minutes at 4
o
C to 
pellet the bacteria and leave phage-containing supernatant. The phage-containing 
supernatant was transferred into microcentrifuge tubes and centrifuged again at 12000 
RPM for 10 minutes at 4
o
C to pellet any residual bacteria remaining within the 
supernatant. After the last centrifugation, 1.2 mL of supernatant was transferred into a 
microcentrifuge tube containing 200 μl of 20% PEG 8000 (Polyethylene Glycol 8000), 
2.5 M NaCl labeled P7R1-OUT Amp and P12R1-OUT Amp. Contents were mixed by 
tilting and then allowed to precipitate horizontally overnight at 4
0
C. 
3.2.7 Precipitation and concentration of first round amplified phages 
After overnight incubation at 4
o
C, the Phages are precipitated by the PEG. The 
Phage-PEG precipitate was pelleted by centrifuging the microcentrifuge tubes at 12000 
RPM for 15 minutes at 4
0
C. The supernate was decanted into bleach, leaving behind the 
phage-PEG pellet at the bottom of the microcentrifuge tube. Residual supernatant was 
removed, by using a barrier-tip 200 microliter pipette, after the tubes were centrifuged 
briefly at 12,000 RPM for 10 minutes. The phage-PEG pellets were concentrated through 
resuspension in a final volume of 200 μl and transferred into a new 1.5 mL 
microcentrifuge tube labeled P7R1-OUT Amp and P12R1-OUT Amp. 
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3.2.8 Titration of first round 7 and 12-mer phages 
E. coli ER2738 was grown to reach a log phage (O.D. 600 nm = 0.4 - 0.5) in LB 
tetracycline within a 50 ml Erlenmeyer flask placed in a 37 
o
C shaker at 250 RPM. The 
phage stocks (P7R1-IN, P7R1-OUT, P7R1-OUT Amp, P12R1-IN, P12R1-OUT and 
P12R1-OUT Amp) were each serially diluted by adding 1µl of phage stock to 99 µl of LB 
and vortex to mix to give a 100 fold dilution. The 100 fold dilution was then added to 900 
μl of LB to give a 1000 fold dilution. Subsequent 1:10 serial dilutions were carried out to 
reach a dilution of 10
12
. 100 μl of each serial phage dilution were each added to 200 μl of 
E. coli ER2738 (O.D. 600 = 0.4 - 0.5) in LB. The phage bacteria mixture was then added 
to phage top agar tubes and plated on IPTG/Xgal plates for “blue/white screening”. 
Control plates containing only 200 μl of bacteria with no phages were added to phage top 
agar tubes and plated on IPTG/Xgal plates. IPTG/Xgal plates were incubated at 37
o
C no 
more than 18 hours. After incubation at 37
0
C, the plates are removed and the number of 
pfu counted and titers determined using the formula below [56]: 
pfu x dilution factor 
Amount plated in microliters 
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3.3 Phages 7-mer and 12-mer Second Round Panning on Patient BCRs 
3.3.1 P7R1-Out Amp and P12R1-Out Amp incubation in “Negative subtraction” plate 
“Negative subtraction” and “Positive selection” plates were each prepared as 
described in “Materials and Methods Sections 3.2.1 to 3.2.3” with goat anti-human IgM 
and patients “E” and “P” BCRs. 
Ninety five microliters of P7R1-Out Amp was added to 5 μl of 10% Tween-20 in 
TBS. In the case of P12R1-Out Amp, 10 μl was added to 40 μl of 0.5% Tween-20 in 
TBS. Fifty microliters of diluted P7R1-Out Amp or P12R1-Out Amp suspension was 
added to the “Negative subtraction” well and incubated at room temperature for 1 hour on 
a rocking plate. After 1 hour incubation, the plate was inclined and the 50 μl of unbound 
phages within the well were transferred into a microcentrifuge tube. The well was washed 
3 times with 50 μl of 0.5% Tween-20 in TBS and the washes were added to the initial 50 
μl of Subtracted unbound phages to give a final volume of 200 μl. Five microliters of the 
subtracted unbound phages was kept for titration (P7R2-IN and P12R2-IN) and the 
remaining 195 μl “Subtracted 7-mer or 12-mer phage display library” was kept for 
“Positive selection” plate. 
3.3.2 Subtracted P7R2-IN and P12R2-IN incubation in “Positive selection” plate 
One hundred and ninety five microliters of “Subtracted 7-mer Phage Display 
Peptide library” (P7R2-IN) library was added to the “Positive selection” well and 
incubated for 1 hour at room temperature on a rocking plate. After 1 hour incubation, the 
non-binding phages were rinsed off by emptying the wells and then tapping the plate onto 
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paper towels. The well was then washed 10 times with 200 μl of 0.05% Tween-20 in TBS 
per wash. The bound phages remaining in the ELISA well were eluted with 15 minutes 
gentle rocking with 200μl of elution buffer (0.2 M Glycine, HCl pH 2.2, 1% BSA).  After 
15 minute incubation with the elution buffer, the 200 μl of eluted phages were transferred 
into a 1.5mL microcentrifuge tube containing 30 μl of 1M Tris-HCl pH 9.1. After 
neutralization, 5 μl of the eluate was kept for titration (P7R2-OUT and P12R2-OUT ) and 
the remaining 225 μl of the eluate was amplified by incubating all the eluate in 4 ml of E. 
coli ER2738 in log phase  (O.D. of 0.05) within a 50 ml Erlenmeyer flask for 4.5 hours at 
37
0
C in a shaker at 260 RPM. 
After neutralization, the remaining 225 μl of the eluate (P7R2-OUT and P12R2-
OUT) was amplified, precipitated and concentrated as described in “Materials and 
Methods Section 3.2.6 to 3.2.7” and labeled P7R2-OUT Amp and P12R2-OUT Amp.  
Phages were then titrated as described in “Materials and Methods Section 3.2.8” 
and labeled P7R2-IN, P7R2-OUT, P7R2-OUT Amp, P12R2-IN, P12R2-OUT and P12R2-
OUT Amp. 
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3.4 Phages 7 and 12-mer third round panning on patient BCRs 
3.4.1 P7R2-Out Amp and P12R2-Out Amp incubation in “Negative subtraction” plate 
“Negative subtraction” and “Positive selection” plates were each prepared as 
described in “Materials and Methods Sections 3.2.1 to 3.2.3” with goat anti-human IgM 
and patients “E” and “P” BCRs. 
10
11
 phages from P7R2-Out Amp or P12R2-Out Amp, in 0.05% TBST, were 
incubated in “Negative subtraction” as described in “Section 3.3.1”. Unbound phages 
((P7R3-IN and P12R3-IN) were collected, titrated and then kept for “Positive selection” 
plate. 
3.4.2 Subtracted P7R3-IN and P12R3-IN incubation in “Positive selection” plate 
Positive selection was performed as described in “Section 3.3.2” using P7R3-IN 
and P12R3-IN. Eluted phages P7R3-OUT and P12R3-OUT were titrated, amplified as 
described in “Section 3.2.7” and labeled P7R3-OUT Amp and P12R3-OUT Amp and 
titrated as described in “Section 3.2.9”. 
3.5 Growing E. coli culture overnight 
In a 50 mL falcon tube, 10 µl of tetracycline (20 mg/ml) was added to 10 ml LB 
broth. 1mL of the LB tetracycline was transferred into a 50 ml falcon tube and inoculated 
with an E. coli ER2738 clone, using a sterile pipette tip to pick an isolated colony from a 
streaked plate. The tube was placed in a shaker at 37
0
C at 260 rpm overnight.   
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3.6 Amplification of selected clones of first, second and third round 7 and 12-mer 
selections 
The number of plaques on an IPTG/Xgal plate with less than 100 blue plaques 
was counted for first, second, and third round “OUT”. An overnight culture of bacteria 
was diluted 1:100 in LB tetracycline medium and 2 mL of the diluted culture was 
dispensed into 5 ml polystyrene culture tubes, one for each clone to be characterized. Ten 
of the well separated blue plaques from each plate were selected, using a sterile 200 
microliter pipette tip and placed in the 2 ml LB tetracycline diluted E. coli culture (O.D. 
0.01 - 0.05). The polystyrene tubes were incubated at 280 rpm for 4.5 to 5 hours at 37 
0
C. 
After incubation, 1.4 mL of each culture was transferred into separated 1.5 ml 
microcentrifuge tubes. The tubes were centrifuge at 14,000 RPM for 30 seconds at 4
o
C to 
pellet the bacteria and leave the phages in supernatant. 1.2 μl of the supernate was 
transferred into a microcentrifuge tube containing 200 μl of 20% PEG8000, 2.5 M NaCl. 
The contents of the tubes were mixed by tilting. The phages were allowed to precipitate 
overnight at 4
0
C positioned horizontal. After overnight incubation at 4
o
C, the phages are 
precipitated by the PEG. The phage-PEG precipitate was pelleted by centrifuging the 
microcentrifuge tubes at 12000 RPM for 15 minutes at 4
0
C.  The supernatant was 
decanted, with phage-PEG pellet remaining at the bottom of tube. Residual supernatant 
was removed by using a barrier-tip 200 microliter pipette after the tubes were centrifuged 
briefly. The phage-PEG pellets were concentrated through resuspension in a final volume 
of 50 μl and transferred into a new microcentrifuge tube. 
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3.7 Phage DNA extraction from amplified clones 
Forty microliters of the concentrated phage clones were each added to 460 μl of 
TBS in a 1.5 mL microcentrifuge tube containing 200 ul of 20% PEG 8000, 2.5 M NaCl. 
Tubes were inverted several times to mix contents of the tube and left to stand for 15 
minutes at room temperature. Tubes were centrifuged at 13000 RPM for 10 minutes at 
4
0
C and the supernatant discarded. Tubes were centrifuged again, briefly, to discard 
remaining supernatant. Each pellet was thoroughly resuspended in 100 μl of Iodide 
Buffer by vigorously tapping the tube. Two hundred and fifty microliters of 96% ethanol 
was added to each tube, mixed and incubated for 15 minutes at room temperature. Tubes 
were then centrifuged at 13,000 RPM for 10 minutes at 4
0
C and the supernate discarded. 
The pellet was then washed with 500 microliters of 70% ice-cold ethanol without 
disturbing the pellet. Tubes were centrifuged at 12,000 RPM for 10 minutes and the 
supernatant was discarded. The pellet was left to air-dry for 5 to 10 minutes at room 
temperature and the pellet was then resuspended in 20 μl of 1X TE pH8.0. Ten 
microliters of each extracted phage clone DNA added to 2 μl of 6x loading Dye (NEB, 
Cat No. B7021S) and run against 0.5 micrograms of M13 sDNA (N4040S Lot. No. 
0130907) in a 0.7% agarose I gel (Figure 28). DNA was sent with sequencing primer 
(96GIII) to Retrogen, Inc (San Diego, Ca) for sequencing to determine the peptide 
expressed on each phage coat protein (Figure 29).  
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3.8 Strategy 2: Phages 7-mer first round panning on CLL patient BCRs 
To reduce the possibility of selection for phages binding to goat anti-human IgM 
antibody, in the “positive selection” plate, used to capture the patient BCRs, a new 
approach was devised. As shown in Figure 35 and detailed below, for the first round 
selection, wells were sensitized with goat-anti-human IgM and incubated with 7-mer 
Phage Display Library (10
11 
phages) to remove any phages binding to the goat anti-
human IgM. Patient “E” BCRs were then captured using goat anti-human IgM onto an 
ELISA plate and then incubated with the subtracted phage library to remove, from the 
supernate, any phages binding to CLL patient “E” BCRs. Patient “P” BCRS were then 
captured on the plate using goat anti-human IgM and then incubated with the subtracted 
phage library coming out patient “E” subtraction well. Unbound phages were washed off 
and bound phages were eluted, titrated, amplified using E. coli ER2738, precipitated and 
then titrated. In the second round selection, 10
7 
amplified phages were incubated in 7 
successive goat anti-human IgM subtractions then transferred to patient “E” BCR 
captured well and then incubated in patient “P” BCRs captured well. Bound phages were 
eluted, titrated, amplified, precipitated and then titrated for the third round selection.  
This was repeated again for the third round selection. 
3.8.1 Sensitization of wells with anti-human IgM for “Negative Subtraction” plates 
Thirty two microliters (32µg) of goat anti-human IgM was added to 768 µl of 0.1 
M NaHCO3 pH8.6 to give a concentration of 0.04µg goat anti-human IgM per µl. Wells 
1, 2, 3 and 4 where each sensitized with 2 µg goat anti-human IgM in volumes of 50 µl, 
100 µl, 150 µl and 200 µl, respectively. Plates were incubated for 1 hour at room 
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temperature. After 1 hour incubation, Wells 1, 2, 3 and 4 were washed 6 times with 
TBST in volumes of 50 µl, 100 µl, 150 µl and 200 µl, respectively. Wells were then 
blocked with 300 µl blocking buffer (0.1 M NaHCO3 pH8.6, 5mg/ml BSA) and 
incubated at 4
0
C overnight. 
3.8.2 Phage Display Library 7-mer incubation in “Negative Subtraction” plate 
Ten microliters of 7-mer Phage Display Library (10
11
pfu) was added to 40 µl of 
TBST. The 50 µl goat anti-human IgM sensitized well was washed 6 times with 50 ul 
TBST and incubated with the Phage Display library for 1 hour at room temperature. The 
100 µl goat anti-human IgM sensitized well was washed 6 times with 100 µl TBST and 
phages were added to the 50 µl well. After seven subtractions using anti-human IgM 
sensitized wells, unbound phages were incubated in patient “E” BCR captured wells 
(using goat anti-human IgM). 
3.8.3 Capturing patient “P” BCRs on anti-human IgM “Positive Selection” plate 
The 200 µl goat anti-human IgM sensitized well was washed 6 times with 200 µl 
of TBST and incubated at room temperature, with 200 µl of diluted patient “P” cell lysate 
after adding 40 µl patient “P” cell lysate to 160 µl TBS. 
3.8.4 Subtracted 7-mer phages (I7R1-IN) incubation in “Positive Selection” plate 
Patient “P” BCR-bound well was then washed 6 times with 200 µl of TBST and 
incubated with the phages after their incubation in the 150 µl patient “E” well for 1 hour 
at room temperature. After incubation of the phages in the patient “P” well, the well was 
washed 10 times with TBST. Two hundred microliters of Glycine HCL pH 2.2 was added 
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for 15 minutes to elute the phages bound to patient “P” BCRs. Supernate containing 
eluted phages were then neutralized with 30 µl of Tris-HCl pH 9.1 and then amplified 
with 20 ml of E. coli at 0.01-0.05 O.D. in a shaker at 265 RMP at 37 
0
C for 4 ½ hours, 
precipitated and the titer determined (I7R1-Out Amp). 
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3.9 Phage Display Library 7-mer second round panning on CLL patient BCRs 
3.9.1 Sensitization of wells with anti-human IgM for “Negative Subtraction” plates 
Wells were sensitized with goat anti-human IgM (1µg per well) using 17 µl of 
goat anti-human IgM with 1.683 ml of 0.1M NaHCO3 pH 8.6 resulting in 1ug per 100 µl. 
One hundred microliters (1µg goat anti-human IgM) of above was then added to each of 
7 wells and incubated for 1 hour at room temperature. After 1 hour incubation at room 
temperature, the wells were washed 6 times with 100 µl TBST and then blocked with 300 
µl blocking buffer (0.1 M NaHCO3 pH8.6, 5mg/ml BSA) and incubated overnight at 4
o
C. 
3.9.2 Capturing patient “E” BCRs on anti-human IgM “Negative Subtraction” plate 
Patient “E” well was sensitized with 2 µg (goat anti-human IgM) per 100 µl. 10 µl 
of patient “E” lysate was added to 40 ul TBS and 50 ul TBST(0.05% Tween-20) and 
incubated, 1 hour at room temperature, in patient “E” well after washing the well 6 times 
with TBST.  
3.9.3 Phages I7R1-out Amp incubation in “Negative Subtraction” plate 
The 1 µg per 100 µl goat anti-human IgM sensitized wells were washed 6 times 
with TBST and incubated with I7R1-Out Amp (10
7 
phages in TBST) for 1 hour at room 
temperature and then transferred from one well into the next for subtraction of all anti-
IgM binding phages. After the last incubation of the phages in the 7
th
 anti-human IgM 
well, the phages were transferred to the patient “E” BCR-captured well and incubated for 
1 hour at room temperature. 
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3.9.4 Capturing patient “P” BCRs on anti-human IgM “Positive Selection” plate 
Patient “P” well was sensitized with 2 µg (goat anti-human IgM) per 100 µl. The 
100 µl goat anti-human IgM sensitized well was washed 6 times with 100 µl of TBST 
and incubated at room temperature, with 100 µl of diluted patient “P” cell lysate after 
adding 40 µl patient “P” cell lysate to 60 µl TBS. 
3.9.5 Subtracted 7-mer phages (I7R2-IN) incubation in “Positive Selection” plate 
 Patient “P” well was washed 6 times with TBST after which phages from patient 
“E” well were transferred into patient “P” well and incubated for 1 hour at room 
temperature. The well was washed 10 times with 100 µl TBST. After the last wash, 100 
µl of Glycine HCl pH 2.2 was added to the well for 15 minutes to elute bound phages and 
then transferred to a microcentrifuge tube containing 15 µl of Tris-HCl pH 9.1. After 
neutralization, 15 µl of the phages was kept in an eppendorf tube for titration (I7R2-
OUT). The rest of the eluted phages were then amplified for 4 ½ hours with 20 ml of E. 
coli at an O.D. of 0.01-0.05,  precipitated overnight in PEG and then concentrated in 
200µl of TBS (I7R2-OUT Amp). 
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3.10 Phage Display Library 7-mer third round panning on CLL patient BCRs 
3.10.1 Phages I7R2-Out Amp incubation in “Negative Subtraction” plate 
Wells were sensitized with goat anti-human IgM for “Negative subtraction” plate 
as described in “Materials and Methods Section 3.9.1”. Patient “E” BCRs were captured 
as described in “Materials and Methods Section 3.9.2” 
I7R2-Out Amp (10
7 
phages in TBST) were subtracted in 7 successive goat anti-
human IgM wells as described in “Section 3.9.3”. 
3.10.2 Subtracted 7-mer phages (I7R3-IN) incubation in “Positive Selection” plate 
Patient “P” BCRs were captured onto “Positive selection” plate as described in 
“Materials and Methods Section 3.9.4”, incubated with I7R3-IN as described in “Section 
3.9.5”, and bound phages eluted and labeled I7R2-OUT.   
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3.2 Results: 
Captured BCRs withstand Phage Display Library surface panning conditions: BCR 
detection before panning 
In order to qualitatively determine if BCRs could be captured onto a well in a 96-
well plate, the wells were sensitized with goat anti-human IgM and then incubated with 
either IgM standard or cell lysates from CLL patients “E” or “P”. IgM was then detected 
using peroxidase-labeled affinity purified goat anti-human IgM (µ) antibody. As shown 
in Figure 25, a more intense color change was observed in IgM standard and cell lysates 
from patients “E” and “P” wells as compared to the negative control wells indicating 
capture of serum IgM standard or patient BCRs from cell lysates.  
 
 Figure 25. BCR Detection before Phage Display Library Surface Panning. ELISA 
wells indicating detection of captured BCRs from CLL patients “P” and “E” cell lysates 
before panning with Phage Display Library. IgM from Human serum (Standardized 
Human  IgM) is used as a positive control. 
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Selection Strategy 1:  
7-mer Phage Display Library first, second and third round panning on CLL patient 
BCRs 
As illustrated in Figure 26, in separate wells, BCRs from CLL patients “P” and 
“E” were captured using goat anti-human IgM, incubated for 1 hour at room temperature 
and washed 3 times with 0.05% Tween-20 in TBS. Patient “E” BCR-captured well was 
used as the “Negative” subtraction plate to remove 7-mer phages binding to regions other 
than the antigen binding site of the B-cell receptor. Remaining phages were incubated 
with the “Positive” selection patient “P” BCR-captured well for 1 hour at room 
temperature and unbound phages were discarded by washing 10 times with TBS (0.05% 
Tween). BCR-bound 7-mer phages were eluted, amplified and titrated, using E. coli 2738 
(Figure 27). Three rounds of selection were performed. The ratios of P7R1- IN: P7-R1-
OUT from the first, second and third round selections were determined. As shown in 
Table 7, the ratio of P7R1- IN: P7-R1-OUT, P7R2- IN: P7-R2-OUT and P7R3- IN: P7-
R3-OUT showed enrichment from the first to the third round selection.  
After elution, the phages (P7R3-OUT) were amplified, using E. coli ER2738, 
separated from the bacteria by centrifugation and precipitated overnight, using 20% PEG 
8000 (Polyethylene Glycol 8000),  as described in “Materials and Methods”. The Phage-
PEG precipitates were pelleted by centrifuging the microcentrifuge tubes at 12000 RPM 
for 15 minutes at 4
0
C and concentrated through resuspension in a final volume of 200 μl. 
The tube was labeled P7R3-OUT Amp and titer determined using E. coli ER2738. 
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Figure 26. Schematic representation of three rounds of panning using Phage Display 
Peptide Library on CLL Patient membrane-bound IgM (BCRs) from lysates 
captured on goat anti-human IgM antibody. 
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Figure 27.  Phage Titering Plate. Plate shows blue plaques from 10
4
 dilution of phage 
stock used to infect E. coli ER2738 on IPTG/ Xgal LB plates. 
 
 
Table 7. Titration of eluted 7-mer phages from Strategy 1 
 
  
P7 library Phages/ul RATIO (IN:OUT) 
P7 library 3.00 x 10
11
 
 P7R1-IN 6.10 x 10
8
 
 P7RI-OUT 2.24 x 10
2
 3.00 x 10
6
 
P7R1OUT AMP1 1.83 x 10
8
 
 
   P7R2-IN 6.20 x 10
8
 
 P7R2-OUT 4.60 x 10
4
 1.00 x 10
4
 
P7R2-OUT AMP1 5.30 x 10
9
 
 
   P7R3-IN 1.09 x 10
9
 
 P7R3-OUT 1.32 x 10
6
 8.00 x 10
2
 
P7R3-OUT AMP1 7.00 x 10
8
 
 
10
4 
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12-mer Phage Display Library first, second and third round panning on CLL 
patient BCRs 
In separate wells, BCRs from CLL patients “P” and “E” lysates were captured 
using goat anti-human IgM, incubated 1 hour at room temperature and washed 3 times 
with 0.05% Tween-20 in TBS. Patient “E” BCR-captured well was used as the 
“Negative” subtraction plate to remove any12-mer phages binding to regions other than 
the antigen binding site of the B-cell receptor. Remaining phages were incubated with the 
“Positive” selection patient “P” BCR-captured well for 1 hour at room temperature and 
unbound phages were discarded by washing 10 times with TBS (0.05% Tween). BCR-
bound 12-mer phages were eluted, titrated and amplified using E. coli ER2738. Ratio of 
P12R1- IN: P12-R1-OUT from the first, second and third round selections were 
determined. Ratios of P12R1- IN: P12-R1-OUT, P12R2- IN: P12-R2-OUT and P12R3- 
IN: P12-R3-OUT showed enrichment from the first round to the third round selection 
(Table 8) but less when compared to 7-mer selection (Table 7). 
 After elution, the phages (P12R3-OUT) were amplified, using E. coli ER2738, 
separated from the bacteria by centrifugation and precipitated overnight, using 20% PEG 
8000 (Polyethylene Glycol 8000),  as described in “Materials and Methods”. The Phage-
PEG precipitates were pelleted by centrifuging the microcentrifuge tubes at 12000 RPM 
for 15 minutes at 4
0
C, concentrated through resuspension in a final volume of 200 µl. The 
tube was labeled P12R3-OUT Amp and titer determined using E. coli ER2738. 
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Table  8.Titration of eluted 12-mer phages from Strategy 1. 
  
      P12 Library Phages/ul RATIO (IN:OUT) 
   P12 Library 3.00 x 10
11
 
 
   P12R1-IN 8.30 x 10
7
 
 P12R1-OUT 1.72 x 10
3
 5.00 x 10
4
 
P12R1-OUT AMP1 8.40 x 10
9
 
 
   P12R2-IN 2.30 x 10
8
 
 P12R2-OUT 1.42 x 10
4
 2.00 x 10
4
 
P12R2-OUT AMP1 7.10 x 10
9
 
 
   P12R3-IN 1.19 x 10
9
 
 P12R3-OUT 2.73 x 10
6
 4.00 x 10
2
 
P12R3-OUT AMP1 8.10 x 10
8
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Amplification of selected phage clones of first, second and third round 7 and 12-mer 
selections 
The number of plaques on an IPTG/Xgal plates with less than 100 blue plaques 
were counted for first, second, and third round “OUT”. Approximately, 10 of the well-
separated blue plaques from each plate (P7R2-OUT, P7R3-OUT, P12R2-OUT and 
P12R3-OUT) were each separately isolated, using a sterile 200 microliter pipette tip and 
placed in the 2 ml LB tetracycline diluted E. coli culture (O.D. 0.01 - 0.05) for 
amplification. The phage clones were then precipitated, and phage DNA extracted as 
described in “Materials and Methods”. Extracted phage DNA samples were run with 
M13 sDNA in a 0.7% agarose I gel. As shown in Figure 28, the quantity of the phage 
DNA in each sample was estimated by using DNA gel electrophoresis with M13 sDNA 
as the control. 
   
Figure 28. DNA-gel electrophoresis image of extracted sDNA phage from isolated 
phage clones and M13 sDNA control. M13 sDNA is used as a ladder and semi-
quantification of concentration of extracted phage clones sDNA. 
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The sDNA phage clone samples were sent together with sequencing primer 
(96GIII) to Retrogen, Inc (San Diego, Ca) for sequence analysis to determine the peptide 
expressed on each phage coat protein. As shown in Figure 29, the 7-mer or 12-mer 
peptides are flanked by “SHS” and “GGG-SAE” sequences. 
7-mer phage clone 
 
12-mer phage clone 
 
Figure 29. Sequence analysis of sDNA phage clones translated. Translation of a 7-mer 
and 12-mer phage clone showing sequence of peptide expressed on phage coat protein. 
Peptide is flanked by “SHS” and “GGG-SAE” sequences. Top: 7-mer phage clone 
translation. Bottom: 12-mer-phage clone translation. 
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As shown in Table 9a and b, translated sDNA from 7-mer phages of second and 
third round selections showed a consensus “LLPPAR_” sequence. “LLPPAR_” sequence 
was also found in sDNA from 12-mer phage clones of second and third round selections 
(Table 10a and b). 
Table 9a. Amino acid sequences of second round isolated 7-mer phages from 
Strategy 1. 
 
Clone Amino acid sequence 
    
P7R2 Clone 1-A  S T W T S V I 
  P7R2 Clone 2-B L L P P A R L 
  P7R2 Clone 3-C Q L L L S P T 
  P7R2 Clone 4-D L L P P A R L 
  P7R2 Clone 5-E L L P P H R L 
  P7R2 Clone 6-F L L S P A R L 
  P7R2 Clone 7-G L L P P A R L 
  P7R2 Clone 8-H L Q P F Q A R 
  P7R2 Clone 9-I L L P P S R L 
  P7R2 Clone 10-J L L P P A R I 
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Table 9b. Amino acid sequences of third round isolated 7-mer phages from Strategy 
1. 
Clone Amino acid sequence   
P7R3 Clone 2-A  L L S P A R L 
 P7R3 Clone 3-B L L P P H R I 
 P7R3 Clone 4-C G L T F A X X 
 P7R3 Clone 5-D* L L P P A R E 
 P7R3 Clone 6-E L L P P H R L 
 P7R3 Clone 7-F L L P P A R F 
 P7R3 Clone 8-G L L P P H R L 
 P7R3 Clone 9-H L L P P A R L 
 P7R3 Clone 10-I L L P P A R D 
 P7R3 Clone 11-J L L P P A R L  
“X” – denotes missing amino acid from difficulty in translating nucleotide sequences. 
 
Table 10a. Amino acid sequences of second round isolated 12-mer phages from 
Strategy 1. 
Clone Amino acid sequence 
  
P12R2 Clone 1-A  T S D Q M V R L H G L K 
 P12R2 Clone 2-B G L L T P H R E T L T T 
 P12R2 Clone 3-C L L S P H R F N I Y P E 
 P12R2 Clone 4-D W G K A W L I P Y P H S 
 P12R2 Clone 5-E L L P P A R E L E N Y N 
 P12R2 Clone 6-F V P Y T L L M P H R V T 
 P12R2 Clone 7-G G L T F S H P T L Q L R 
 P12R2 Clone 8-H L I P P H R D H L G S H 
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Table 10b. Amino acid sequences of third round isolated 12-mer phages from 
Strategy 1. 
Clone Amino acid sequence   
P12R3 Clone 2–A L L S P A R C T P Y C V 
 P12R3 Clone 3-B S L L Q P A R E Y L A M 
 P12R3 Clone 4-C Y L E P A R Q Q V Q R X 
 P12R3 Clone 5-D L L P P H R T M G T G X 
 P12R3 Clone 6-E A H F P P C C R T S N X 
 P12R3 Clone 7-F T L I Q P H R L Q Q L X 
 P12R3 Clone 8-G S L L P P H R L H Y S F 
 P12R3 Clone 9-H Q Q P V S P A D L F I X 
 P12R3 Clone 10-I N L L P P A R L Q L A X 
 P12R3 Clone 11-J A S H D E I W L X V X X  
“X” – denotes missing amino acid from difficulty in translating nucleotide sequences. 
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Concentration of amplified phage clone “LLPPARE” by phage ELISA 
Phage Clone “LLPPARE” and M13 were amplified and relative titers determined. 
As illustrated in Figure 30A and B, serial dilutions of P7R3 Clone 5-D (LLPPARE) and 
M13 phages starting with 1.25 x 10
9 
pfu in NaHCO3 pH 8 were prepared and used to 
sensitize ELISA wells. The plate was incubated for 1 hour at room temperature, washed 6 
times, blocked with blocking buffer and incubated overnight at 4
0
C. All wells were 
washed 10 times and incubated with biotinylated mouse anti-M13 antibody and then with 
streptavidin horseradish peroxidase (SHRP) biotin. 1-Step
TM
 Ultra TMB-ELISA substrate 
was added to each well and the reaction stopped using 1M sulfuric acid. The plate was 
read at 450 nm. As shown in Figure 30 C, amplified “LLPPARE” and M13 had same 
titers and could be used to determine binding to patient-captured BCRs. 
A.        B. 
 
C. 
 
Figure 30. Concentration of Amplified Phage Clone “LLPPARE” by Phage ELISA. 
A and B. Diagrams showing wells to detect serially diluted phage clone M13 and 
“LLPPARE”, respectively. C. Graph showing relative concentrations of “LLPPARE” and 
M13 wildtype phages. 
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Using P7R3 clone 5-D “LLPPARE” on CLL patient “P” BCR 
As illustrated in Figure 31 A and B, wells in an ELISA plate were sensitized with 
1.2 µg goat anti-human IgM per well. The ELISA plate was incubated for 1 hour at room 
temperature, washed 6 times and blocked with blocking buffer and incubated overnight at 
4
0
C. CLL patient “P” BCR were captured on goat anti-human IgM sensitized plate, 
washed and incubated, for 1 hour at room temperature, with serial dilutions of 
P7R3Clone 5-D (LLPPARE) or M13 phages starting with 1.25 x 10
9 
pfu. All wells were 
washed 10 times and incubated with biotinylated mouse anti-M13 antibody and then with 
streptavidin horseradish peroxidase (SHRP) biotin. 1-Step
TM
 Ultra TMB-ELISA substrate 
was added to each well and incubated at room temperature , reaction stopped using 1M 
sulfuric acid
 
and read at 450 nm using an ELISA plate reader. As shown in Figure 31C, 
“LLPPARE” shows higher binding to patient “P” BCR-captured well as compared to the 
M13 phages. However, it is not clear whether “LLPPARE” binds to CLL patient “P” 
BCR or goat anti-human IgM in the wells. 
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  A.           B. 
 
    
 
 
C. 
.
 
Figure 31. “LLPPARE” binds Patient “P” BCRs captured using goat anti-human 
IgM. A and B. Diagrams showing detection method for binding of phages by incubating 
phage clone M13 and “LLPPARE” on  patient “P” BCRs which were captured onto goat 
anti-human IgM sensitized wells. C. Graph showing the absorbance values of the Phage 
ELISA to investigate binding of serial dilutions of “LLPPARE” and M13 phage clones 
against CLL patient “P” BCRs which were captured using goat anti-human IgM.
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Does “LLPPARE” bind to goat anti-human IgM antibody or patient BCR? 
As illustrated in Figure 32A, B, C and D, wells were sensitized with goat anti-
human IgM (1.2 µg), blocked and incubated at 4
0
C overnight. Wells were washed 6 times 
and incubated with serial dilutions of IgM from human serum, CLL patients “P” and “E” 
cell lysates and as a control some wells were left without Human IgM.  1.25 x 10
9
 pfu of 
phage clone “LLPPARE” was added to each well and incubated for 1 hour at room 
temperature. Wells were washed 10 times, incubated with biotinylated mouse anti-M13 
and streptavidin horseradish peroxidase.  1-Step
TM
 Ultra TMB-ELISA substrate was 
added to each well incubated at room temperature, reaction stopped using 1M sulfuric 
acid
 
and read at 450 nm using an ELISA plate reader and graphed. As shown in Figure 
32E, there was no change in using serial dilutions of Human IgM, CLL patients “E” or 
“P” lysates, as compared to the control wells which did not receive IgM of any kind. 
“LLPPARE” binds to the goat anti-human IgM wells at the same absorbance as the serum 
IgM or BCR-captured wells, suggesting that “LLPPARE” binds goat anti-human IgM 
antibody. After performing a database search of “LLPPARE”, it was found to be located 
on the hydrophilic region of the CH4 domain of the human IgM molecule (Figure 34). 
“LLPPARE” was therefore selected for by the goat anti-human IgM antibodies which 
were used to capture patient BCRs onto the wells. 
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A.    B.        C.             D. 
   
 
E. 
 
Figure 32. “LLPPARE” binds goat anti-human IgM.  A, B, C and D. Diagrams showing the detection, using biotinylated anti-
phage antibody, of phage clone “LLPPARE” binding to patient “P”, “E”BCRs and Human IgM (captured onto goat anti-human IgM 
sensitized wells) and goat anti-human IgM,  respectively. E. Graph showing the absorbance from incubation of “LLPPARE” (1.25 x 
10
9
 pfu) phages onto dilutions of BCRs from patient “E”, “P” lysates and Human standard captured using goat anti-human IgM.  
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As a control to detect the presence of serum IgM or patient BCRs in dilution, used 
in the above experiment, wells were sensitized with 1.2 µg of anti-human IgM and 
incubated with the same dilutions of serum IgMs or BCRs used for the phage wells to 
detect the presence of IgM within the prepared lysates. Wells were incubated with the 
IgMs, washed 6 times and incubated with goat anti-IgM HRP. IgMs were detected using 
goat anti-human IgM peroxidase starting with patient “P”, “E” and Human IgM wells. As 
shown in Figure 33, the presence of IgM captured using goat anti-human IgM was 
confirmed to be present in serial dilutions of lysates and human serum IgM . 
A.                    B. 
                   
 
C.
 
Figure 33. IgM detection within IgM Standard from human serum and BCR 
detection within CLL patients "P" and E" cell lysates. A and B. Diagrams showing 
IgM detection within serum IgM and patients “E” and “P” cell lysates used in testing the 
binding of “LLPARE” clone.  C. Graph shows binding from serially diluted IgM from 
human serum, patients "P" and E" cell lysates onto goat anti-human IgM. 
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ProtScale 
User-provided sequence: 
  10         20         30         40         50         60  
GVALHRPDVY LLPPAREQLN LRESATITCL VTGFSPADVF VQWMQRGQPL SPEKYVTSAP  
 
        70         80         90  
MPEPQAPGRY FAHSILLTVS EEEWNTGETY TCV  
 
 
Figure 34. Hydrophobicity plot of “LLPPARE” sequence in CH4 region of human 
IgM molecule (Fc region). Diagram shows hydrophobicity of CH4 region of Human 
IgM using Kyte & Doolittle (http://web.expasy.org/cgi-bin/protscale/protscale.pl?1) 
  
LLPPARE 
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Selection Strategy 2: 
7-mer Phage Display Library three rounds of panning on CLL patient BCRs 
In order to reduce the possibility of phages binding to goat anti-human IgM 
antibody used to capture the patient BCRs, a new approach was devised. As shown in 
Figure 35, for the first round selection, wells were sensitized for 1 hour at room 
temperature with 2 μg goat-anti-human IgM in NaHCO3 pH 8.6, washed 6 times and 
blocked overnight at 4
0
C. 7-mer Phage Display Library (10
11 
phages) in TBST (0.05% 
Tween-20) was incubated with 2 goat anti-human IgM sensitized wells to remove any 
phages binding to the goat anti-human IgM. Patient “E” BCRs were captured using goat 
anti-human IgM and then incubated with the subtracted phage library to remove, from the 
supernatant, any phages binding to CLL patient “E” BCRs. Patient “P” BCRS were then 
captured on the plate using goat anti-human IgM and then incubated with the subtracted 
phage library coming out patient “E” subtraction well (I7R1-IN). Phages were incubated, 
in patient “P” well, for 1 hour at room temperature and then unbound phages were 
washed off using 10 washes with TBST (0.05% Tween-20). Bound phages were eluted, 
titrated (I7R1-OUT), amplified using E. coli 2738, precipitated and then titrated (I7R1-
Out Amp) for the second round selection. 
In the second round selection, 7 wells were sensitized with 1 μg goat anti-human 
IgM in 0.1M NaHCO3 pH 8.6 for 1 hour at room temperature and then blocked overnight 
at 4
0
C. I7R1-Out Amp (10
7 
phages in TBST 0.5% Tween-20) was incubated for 1 hour at 
room temperature and then transferred from one well into the next for 7 successive goat 
anti-human IgM subtraction of all anti-IgM binding phages. After the last incubation of 
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the phages in the 7
th
 anti-human IgM well, the phages were transferred to patient “E” 
BCR well captured using goat anti-human IgM and then incubated for 1 hour at room 
temperature. Patient “P” BCRs were then captured on the plate using goat anti-human 
IgM and then incubated with the subtracted phage library coming out patient “E” 
subtraction well (I7R2-IN). Phages were incubated, in patient “P” well, for 1 hour at 
room temperature and then unbound phages were washed off using 10 washes with TBST 
(0.05% Tween-20). Bound phages were eluted, titrated (I7R2-OUT), amplified using E. 
coli 2738, precipitated and then titrated (I7R2-Out Amp) for the third round selection. 
In the third round selection, 7 wells were sensitized with 1 μg goat anti-human 
IgM in 0.1M NaHCO3 pH 8.6 for 1 hour at room temperature and then blocked overnight 
at 4
0
C. I7R2-Out Amp (10
7 
phages in TBST 0.5% Tween-20) was incubated for 1 hour at 
room temperature and then transferred from one well into the next for 7 goat anti-human 
IgM subtraction of all anti-IgM binding phages. After the last incubation of the phages in 
the 7
th
 anti-human IgM well, the phages were transferred to patient “E” BCR well 
captured using goat anti-human IgM and then incubated for 1 hour at room temperature. 
Patient “P” BCRs were then captured on the plate, using goat anti-human IgM, and then 
incubated with the subtracted phage library coming out of patient “E” subtraction well 
(I7R3-IN). Phages were incubated in patient “P” well for 1 hour at room temperature and 
then unbound phages were washed off using 10 washes with TBST (0.05% Tween-20). 
Bound phages were eluted and titrated (I7R3-OUT). As shown in Table 11a, there was 
enrichment between second round and third round selection titers. First round selection 
could not be used in the comparison because of the high number of phages (10
11
 pfu) 
used in the selection. 
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Figure 35. Strategy 2 schematic representation of three rounds of panning using 7 Phage Display Library on CLL 
Patient BCRs captured on goat anti-human IgM antibody.   
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Table 11a. Titration of eluted 7-mer phages from Strategy 2 phage selection. 
  P7 library Phages/ul RATIO (IN:OUT) 
   I7R1-IN 8.30 x 10
8
 
 I7RI-OUT 2.60 x 10
3
 3.19 x 10
5
 
I7R1OUT AMP1 4.60 x 10
9
 
 
   I7R2-IN 1.50 x 10
5
 
 I7R2-OUT 8.30 x 10
1
 1.81 x 10
3
 
I7R2-OUTAMP1 5.50 x 10
8
 
 
   I7R3-IN 1.10 x 10
5
 
 I7R3-OUT 4.60 x 10
2
 2.39 x 10
2
 
  
   
Amplification of selected clones of third round 7-mer selection 
The number of plaques on an IPTG/Xgal plates with less than 100 blue plaques 
were counted for the third round “OUT”. Approximately, 10 of the well-separated blue 
plaques from each plate (I7R3-OUT) were each separately isolated, using a sterile 200 
microliter pipette tip and placed in the 2 ml LB tetracycline diluted E. coli culture (O.D. 
0.01 - 0.05) for amplification. The phage clones were then precipitated, and phage DNA 
extracted as described in “Materials and Methods”. Extracted phages were run with M13 
sDNA in a 0.7% agarose I gel. The sDNA phage clone sample were sent together with 
sequencing primer (96GIII) to Retrogen, Inc (San Diego, Ca) for sequence analysis to 
determine the peptide expressed on each phage coat protein. 
As shown in Table 11b, the translated sDNA from 7-mer phage clones of the third 
round selection showed a consensus “GFTFMPA” sequence and two other sequences 
“QSRPLLP” and “GLPCCSS”. 
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Table 11b. Amino acid sequences of Third Round isolated 7-mer phages from 
Strategy 2. 
 
Name Amino acid sequence   
I7R3 Clone 1-A  GFTFMPA 
 
 I7R3 Clone 2-B GFTFMPA 
 
 I7R3 Clone 3-C GFTFMPA 
 
 I7R3 Clone 4-D GFTFMPA 
 
 I7R3 Clone 5-E QSRPLLP 
 
 I7R3 Clone 6-F GLPCCSS 
 
 I7R3 Clone 7-G GFTFMPA 
 
 I7R3 Clone 8-H GFTFMPA 
 
 I7R3 Clone 9-I GFTFMPA 
 
 I7R3 Clone 10-J GFTFMPA    
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Determining concentrations of amplified clones selected in Strategy 2 before testing 
their binding to goat anti-human IgM 
Before proceeding to test binding of phage clones “GFTFMPA”, “QSRPLLP”, 
“GLPCCSS”, and “LLPPARE”, their relative concentrations were determined. As 
illustrated in Figure 36A, starting with 10
10
 phages, the phage clones were serially diluted 
(2-fold), used to sensitize an ELISA well, incubated for 1 hour at room temperature, 
washed and blocked overnight at 4
0
C. The ELISA plate was then washed 10 times with 
TBST and then incubated with biotinylated mouse anti-phage antibody and then 
streptavidin peroxidase. TMB-ELISA substrate was added to each well, incubated at 
room temperature, the reaction stopped using 1M H2SO4
 
and absorbance read at 450 nm. 
Phage clones (GFTFMPA, QSRPLLP, GLPCCSS, and LLPPARE) dilution optical 
densities were comparable (Figure 36B) and used in anti-IgM binding determination 
experiment.  
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A. 
 
 
B. 
 
Figure 36. Concentration of Amplified Phage clones “GFTFMPA”, “QSRPLLP”, “GLPCCSS” and “LLPPARE” by Phage 
ELISA.  A. Diagram showing detection method for relative concentrations of phage clones. B. Graph showing the relative 
concentrations of Phage clones “GFTFMPA”, “QSRPLLP”, “GLPCCSS” and “LLPPARE”.
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Determining whether clones selected in Strategy 2 bind to goat anti-human IgM 
As illustrated in Figure 37A, ELISA wells were sensitized with 1 μg goat anti-
human IgM per well and incubated at room temperature for one hour. Wells were washed 
6 times with TBST and blocked with blocking buffer (0.1M NaHCO3 pH 8.6, 5 mg/ml 
BSA) overnight at 4
0
C. For a negative control, empty wells received no goat anti-human 
IgM but were blocked overnight at 4
0
C (Figure 37B). Wells were then washed and 
incubated with 10
10
 pfu of each Phage clone “GFTFMPA”, “QSRPLLP”, “GLPCCSS”, 
or “LLPPARE”. The plate was incubated for 1 hour at room temperature, washed 10 
times with TBST, incubated with mouse anti-phage biotin with final addition of 
streptavidin peroxidase. TMB-ELISA substrate was added to each well, incubated at 
room temperature, the reaction stopped using 1M sulfuric acid
 
and absorbance read at 
450 nm.  
As shown in Figure 37C, phage clones “GFTFMPA”, “GLPCCSS” and 
“LLPPARE” each showed higher binding to goat anti-human IgM. In contrast, phage 
clone “QSRPLLP” did not show higher binding to the goat anti-human IgM antibody and 
was similar to the negative control absorbance for non-specific binding (Figure 37C). 
Background optical density of each clone was below absorbance value of 0.5 O.D 
indicating that the optical densities obtained for “GFTFMPA”, “GLPCCSS” and 
“LLPPARE” was due to binding to goat anti-human IgM. In addition, “LLPPARE” 
phage clone was used as a control and showed binding to the goat anti-human IgM. 
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A.            B. 
 
 
 
 
C. 
 
 
 
Figure 37. “GFTFMPA”, “GLPCCSS” and “LLPPARE” Phage Clones Bind to 
Goat Anti-Human IgM. A. Phage clones serially diluted and incubated with goat-anti 
human IgM to test binding. B. As a negative control, the phage clones were only 
incubated with blocked well to determine non-specific binding. C. Graph showing the 
binding from incubation of 10
10
 pfu phages clones “GFTFMPA”, “QSRPLLP”, 
“GLPCCSS” and “LLPPARE” with goat anti-human IgM sensitized wells. 
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Using IgM from human serum captured on anti-human IgM to determining binding 
of selected clones “GFTFMPA”, “QSRPLLP” and “LLPPARE” 
To determine whether selected phage clones “GFTFMPA”, “QSRPLLP” and 
“LLPPARE” bind to IgM standard from human serum, and ELISA was performed as 
illustrated in Figure 38A and B. ELISA wells were sensitized with 1 µg of goat anti-
human IgM, washed and blocked overnight at 4
0
C. Wells were then incubated with 2-fold 
serial dilutions of human IgM standard (starting with 800 ng). Wells were then incubated 
with each phage clone (1.25 x 10
9
pfu per well) for 1 hour at room temperature and 
washed 10 times with TBST and then incubated with biotinylated mouse anti-phage 
antibody followed by streptavidin horseradish peroxidase. 1-Step
TM
 Ultra TMB-ELISA 
substrate was added to each well, incubated at room temperature, stopped with 1M 
sulfuric acid and absorbance read at 450 nm. As shown in Figure 38C, “GFTFMPA” and 
“LLPPARE” showed higher binding at an optical density of 3.764 to Human IgM 
captured using goat anti-human IgM and this could be the due to the binding of these 
phage clones to goat anti-human IgM.  However, “QSRPLLP” showed no binding to the 
captured IgM with a maximum optical density of 0.359. This shows that “QSRPLLP” 
does not bind to IgM from human serum.  
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A.           B. 
   
C. 
 
Figure 38. “QSRPLLP” does not bind Serum IgM.  A. Diagram showing the order of 
goat-anti-human IgM, IgM from human serum and phage clones “GFTFMPA”, 
“QSRPLLP” and “LLPPARE”. B. Binding of phage clones to goat anti-human IgM wells 
with no IgM present C. Graph showing absorbance from binding of Clones 
“GFTFMPA”, “QSRPLLP” and “LLPPARE” on serially diluted human IgM standard 
captured using goat anti-human IgM. 
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Binding of phage clone “QSRPLLP” to patients “P” and “E” BCRs captured on 
goat anti-human IgM 
AS illustrated in Figure 39A and B, binding of Phage Clone “QSRPLLP” was 
tested against CLL patients “P” and “E” BCRs which were captured onto an ELISA plate 
using goat anti-human IgM. Binding was determined by using 2-fold serial dilutions of 
patients “P” and “E” BCR-containing lysates captured on 1 µg goat anti-human IgM. 
Wells were washed and incubated with “QRSPLLP” phage clone (1.25 x 10
9
pfu per well) 
for 1 hour at room temperature, washed, incubated with biotinylated mouse anti-phage 
antibody and then incubated with streptavidin horseradish peroxidase. 1-Step
TM
 Ultra 
TMB-ELISA substrate was added to each well, incubated at room temperature, stopped 
with 1M sulfuric acid
 
and absorbance read at 450 nm. As shown in Figure 39C, 
“QSRPLLP” phage clone showed the same optical density from binding to CLL patient 
“P” and “E” BCRs captured wells with a maximum optical density of 0.78 O.D. with 
both CLL patients. As a control, “QSRPLLP” phage clone was incubated with goat anti-
human IgM sensitized well only. The results showed that “QSRPLLP” was binding to 
BCR of Patients “E” and “P” and not the result of background binding.  
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A.        B. 
       
C. 
 
Figure 39. Binding of Phage Clone “QSRPLLP” to Patients “P” and “E” BCRs 
captured using goat anti-human IgM antibody. A and B.  Diagrams showing the order 
of goat-anti-human IgM, patients “E” or “P” BCRs and phage clones on an ELISA plate 
used to determine binding of “QSRPLLP” clone on patients “E” and “P” BCRs captured 
using goat anti-human IgM. C. Graph showing absorbance from binding of Phage Clone 
“QSRPLLP” on serially diluted patient “E” and “P” BCRs captured using goat anti-
human IgM. 
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As illustrated in Figure 40A, BCR concentration within CLL patients “E” and “P” 
lysates were also determined by capturing BCRs from serially diluted patient lysates, 
using goat anti-human IgM and then incubated with horseradish peroxidase labeled goat 
ant-human IgM. 1-Step
TM
 Ultra TMB-ELISA substrate was added to each well, incubated 
at room temperature, stopped with 1M sulfuric acid and read at 450 nm. As shown in 
Figure 40B, concentrations of BCRs present in CLL patients “E” and “P” lysates 
decreased with increased dilution of lysates. In addition, both had an initial maximum 
optical density of 3.7. 
A. 
 
B. 
 
Figure 40. Detection of CLL Patients “P” and “E” BCRs captured using goat anti-
human IgM. A. Schematic representation of ELISA used to determine presence of BCRs 
within lysate used to determine binding of “QSRPLLP” phage clone. B. CLL patients “P” 
and “E” lysates serially diluted, and their BCRs captured onto an ELISA plate using goat 
anti-human IgM and then detected using horseradish peroxidase-conjugated goat anti-
human IgM. 
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Identification of apoptotic cells within Patients “P” and “E” PBMCs 
Frozen patient “P” PBMC cryovial was quickly thawed and washed with 10% 
FCS in RPMI. The patient cells were resuspended in 1ml flow buffer (PBS, 2mM EDTA, 
1% BSA). Hundred thousand cells were aliquoted per flow tube.  Patient “P” cells were 
stained for Annexin-V and propidium iodide and incubated for 1 hour on ice. The cells 
were then washed 3 times with flow buffer and then fixed with 1% paraformaldehyde in 
PBS and read using an Accuri C6 flow cytometry. As shown in Figure 41, FCS versus 
SSC shows two distinct lymphocyte populations, regions “R3” and “R4”.  Annexin-V 
and propidium iodide-stained cells were excluded from the FCS and SSC plot by using 
Markers “M1” and “M2” from  the histograms of propidium iodide and Annexin-V plots, 
respectively. Region “R3” was the only lymphocyte population remaining after excluding 
Annexin-V and propidium iodide stained cells (Figure 41). 
 
 
Figure 41. Flow Cytometry Distinguishing the Two B-lymphocyte Regions Observed 
in CLL Patients. PBMCs from CLL patient “P” were incubated with stained for 
Annexin-V and propidium iodide location of apoptotic cells. 
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Testing phage clones “GFTFMPA”, “QSRPLLP” and “LLPPARE” on CLL 
patients “P” and “E” PBMCs 
Phage clones “GFTFMPA”, “QSRPLLP” and “LLPPARE” were each incubated 
against CLL patient “E’ and “P” PBMCs to determine binding to CLL B-cells. Patients 
“P” and “E” frozen PBMC cryovials was quickly thawed and washed with 10% FCS in 
RPMI. The patient cells were each resuspended in 1ml flow buffer (PBS, 2mM EDTA, 
1% BSA). Fifty thousand cells were aliquoted per flow tube.  Patient “P” and “E” cells 
were separately incubated for 1 hour on ice with each of the clones “GFTFMPA”, 
“QSRPLLP” and “LLPPARE”. The cells were then washed 3 times with flow buffer and 
incubated for 30 minutes on ice with mouse anti-phage biotin. Cells were washed 3 times 
with flow buffer and then incubated for 30 minutes on ice with Streptavidin-FITC and 
anti-CD19 antibodies. Cells were washed 3 times with flow buffer and then fixed with 
1% paraformaldehyde in PBS and read using an Accuri C6 flow cytometry. As shown in 
Figure 42 and 43, B cells were identified using anti- CD19 antibodies and two regions 
“R1” and “R2” were created. By gating on Region “R1” and looking at CD19 versus 
Anti-phage FITC for the three phage clones incubated with patients “E” and “P” PBMCs, 
no change was observed indicating that phage clones “GFTFMPA”, “QSRPLLP” and 
“LLPPARE” did not bind to the exposed region of surface BCR on B cells. 
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Figure 42. Flow Cytometry Testing the Binding of Phage Clones “GFTFMPA”, 
“QSRPLLP” and “LLPPARE” on CLL Patient “P” PBMCS. 
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Figure 43. Flow Cytometry Testing the Binding of Phage Clones “GFTFMPA”, 
“QSRPLLP” and “LLPPARE” on CLL Patient “E” PBMCS. 
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DISCUSSION 
Phage display peptide libraries have been used to target BCRs of CLL cell. In 
2002, Buhl et al. discovered 9-mer peptides which were specific to the BCR of CLL cells 
from a patient [52]. They did not perform a negative selection and bound the monomeric 
IgM to protein A sepharose. Using flow cytometry, they showed that these phages bound 
to the patient’s CLL cells with intensities more than 10 times higher compared to phage 
binding to CLL cells from other patients. However, there was not further work published 
by this group using this technology. 
An investigated alternate method to targeting the BCRs of CLL cells was to 
express the VH and VL segments of CLL clones as human IgGs in a mammalian vector, 
incubating them with a phage display library and then capturing the peptide-CLL mAb 
complex using Protein A or G agarose beads [57]. However, this methodology is 
cumbersome. The aim of our strategy was to allow for a rapid selection of peptides 
binding specifically to patient-specific CLL cells to benefit many CLL patients in a 
timely manner. 
This work provides an attempt to select patient-specific peptides from phage 
display libraries binding to BCRs of B-CLL cells. We worked with CLL cells from two 
patients. The VH and VL genes from each patient were determined.  Sequence homology 
to germline VH greater than 98% was considered unmutated (U-VH) and less than 98% 
homology was considered mutated (M-VH). CLL cells from patient “P” use VH 1-3
* 
01 
 
103 
 
gene, D 2-2
*
 01 gene and JH 4-02
*
 01 gene with no mutations. In addition, CLL cells 
from patient “P” used variable light chain Vk 1-39
*
 01 gene and JK1 
*
 01 gene with no 
mutations (Figure 4). Thus, the VH and VL portions of the immunoglobulin are identical 
to the germline with no mutations.  CLL cells from patient “E” use VH 4-34
*
 01 gene 
with 2 mutations out of 285 nucleotides (99.30 percent identical), a possible D2-2
*
 01 
gene with 4 mutations out of 16 nucleotides and JH 6-02
*
 01 gene with 1 mutation out of 
58 nucleotides. Also, CLL cells from patient “E” use variable light chain VK5
*
 02 gene 
(Figure 5). Thus, CLL cells from patient “E” show less than 2 percent mutation. Patients 
with U-VH have a poorer prognosis compared to M-VH patients [23]. Therefore, based 
on the molecular analysis of the VH genes, both patients are included in the poor 
prognosis subgroup for CLL. 
Flow cytometry analysis of PBMCs from patients “P” and “E” peripheral blood  
CD5
+
/CD19
+ 
 lymphocytes (Figure 6) showed that 93.8% of the lymphocytes in patient 
“P” PMBCs were CD5
+
/CD19
+
 and using a kappa light chain (Figure 7), confirming 
clonality. However, CLL cells from patient “E” CD5
+
/CD19
+
 showed that 65.2% of these 
cells are kappa
+
 and 26.1% lambda
+ 
(Figure 8). B-CLL with 2 or more distinct B-cell 
clonal populations has been identified in some patients [58, 59]. CLL cells from patient 
“P” showed a decrease in BCR expression compared to patient “E” CD5
+
/CD19
+ 
cells 
and CD19 B-cells from healthy donors (Figure 9). This low expression is consistent with 
CLL, while patient “E” still had surface BCR expression similar to CD19 B-cells from 
healthy donors. These results are consistent with an early stage in the disease of patient E. 
To obtain membrane-bound IgM from both patients, PBMCs were lysed using a 
mild detergent. The membrane-bound IgMs were released from B cell surfaces and IgM 
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presence confirmed by Western blot (Figure 12). The membrane-bound IgMs in the 
patient lysates were semi-quantified against standardized IgM from human serum, by 
capturing with goat anti-human IgM and identifying with anti-human IgM HRP (Figure 
13). Presence of BCRs in patient “P’ was determined to be about four times more 
concentrated than patient “E” cell lysate (Table 4). This is consistent with the higher 
PBMC count obtained during PBMC isolation with patient “P” compared to “E” (Table 
2). 
BCR light chain concentrations were also semi-quantified by capturing the 
membrane-bound IgMs with goat anti-human IgM and using a mouse anti-human kappa 
or lambda monoclonal antibody for detection. Patient “P” had only kappa, while patient 
“E” had both kappa and lambda light chains still present (Tables 5 and 6). The low 
concentration of BCR lambda light chain in patient “P” cell lysate further supports the 
monoclonal CD5
+
/CD19
+
 B-cell population identified in flow cytometry data of kappa 
versus lambda light chain on cell surface of CD5
+
/CD19
+
 B-cells (Figure 7). In addition, 
the presence of both kappa and lambda in patient “E” is in agreement with the kappa 
versus lambda flow data (Figure 8) BCRs within cell lysates. Therefore, the method used 
to solubilize membrane-bound IgM was successful and yielded a high concentration of 
intact membrane-bound IgM. 
Membrane-bound IgMs from patient “P” and “E” were then used to select for 
peptides binding to the antigen binding site of the BCR for patient “P” cells. BCRs from 
patient “E” were used to subtract peptides binding to regions of BCR molecule present in 
both lysates. For this purpose, we used the following strategy (Figure 26): Patient “E” 
BCRs were captured with goat anti-human IgM and this well provided negative selection 
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of the peptide-Phage Display Libraries. The remaining unbound phages were then 
incubated in a well containing patient “P” BCRs to positively select for phages binding to 
patient “P” BCR antigen binding pocket. Two different peptide libraries displaying 7 and 
12-mer peptides were used. Results from Strategy 1 showed enrichment in eluted phages 
in both the 7-mer and 12-mer selections (Table 7 and 8). Eight to ten clones were selected 
and a sequence consisting of a “LLPPAR_” peptide was found in both 7 and 12-mer 
libraries (Table 9b). Phages displaying peptide “LLPPARE” showed higher binding, 
compared to M13 phages, when incubated with patient “P” BCRs which were captured 
using goat anti-human IgM (Figure 31C). To determine whether phages displaying 
peptide “LLPPARE” were binding to patient “P” BCRs or the goat anti-human IgM in 
the well, phages displaying peptide “LLPPARE” were tested for binding to only goat 
anti-human IgM, and then tested against patients “E”, “P” BCRs and human serum IgM 
captured using goat anti-human IgMs (Figure 32A, B, C and D). The results showed that 
goat anti-human IgM well had the same optical density as the IgM and patient BCR-
captured wells confirming that phages displaying peptide “LLPPARE” were binding to 
goat anti-human IgMs in the well (Figure 32E) rather than to the BCR from patient “P”. 
Database sequence search of “LLPPARE” showed an identical sequence was located on 
the CH4 hydrophilic region of human IgM (Figure 34). Thus, “LLPPARE” may be the 
core of an immunodominant epitope for goat antibodies on the IgM molecule. 
To remove phages with affinity for the goat anti-human IgM, a new strategy was 
devised. We used two goat anti-human IgM incubations of the peptide-Phage Display 
library in the first round and seven goat anti-human IgM incubations in the second and 
third rounds, prior to positive selection for phages binding to patient “P” captured BCRs 
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(Figure 35). In addition, the input phages in second and third round were also reduced 
from 10
11
 to 10
7
, after the first round selection. The rationale for this decrease in input of 
phages is to ensure that majority of the goat anti-human IgM binding phages were 
removed from the pool in the successive anti-human IgM subtraction wells. Enrichment 
of phages was observed (Table 11a). After the second and third round selection, 
sequencing of the selected phage clones from the positive selection showed 3 different 
phage displaying peptides “GFTFMPA”, “QSRPLLP” and “GLPCCSS” (Table 11b).  
Phages displaying peptides “GFTFMPA”, “QSRPLLP”, “GLPCCSS” and 
“LLPPARE” were then tested for binding to goat anti-human IgM (Figure 37A). The goat 
anti-human IgM-binding “LLPPARE” phage clone was used as a control. Phage clones 
displaying peptides “GFTFMPA” and “GLPCCSS” showed binding to goat anti-human 
IgM. However, phage clones displaying peptide “QSRPLLP” did not show binding to 
goat anti-human IgM antibody (Figure 37C).  
Phages displaying peptides “GFTFMPA”, “QSRPLLP” and “LLPPARE” were 
then tested for binding to IgM from human serum which was captured using goat anti-
human IgM. The results showed significantly higher binding of phage clones displaying 
peptides “GFTFMPA” and “LLPPARE”, as expected due to the presence of goat anti-
human IgMs used to sensitize the wells. However phage clones displaying “QSRPLLP” 
peptide showed no binding to IgM from human serum (Figure 38).  
Phage clones displaying “QSRPLLP” peptide were then tested for binding to 
patient “P” and “E” BCRs which were captured using goat anti-human IgM. The phage 
clones displaying “QSRPLLP” peptides showed same binding to patient “P” and “E” 
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BCR-captured wells (Figure 39). Phage clones displaying “QSRPLLP” peptide were 
therefore binding to a common region of the BCR molecule in patients “P” and “E” 
which is not present in IgM from human serum. 
Phage clones displaying peptide “QSRPLLP” were then tested by flow cytometry 
for binding to intact PMBCs from CLL patients “P” and “E” and analyzed. Phage clones 
displaying peptides “GFTFMPA” and “LLPPARE” were used as negative controls. 
Phages displaying “QSRPLLP” peptides did not bind to patients “P” or “E” B-cells 
(Figures 42 and 43). This suggests that the “QSRPLLP” peptide does not bind to exposed 
regions of membrane-bound BCRs of CLL patient “P” or “E” cells. These results suggest 
that “QSRPLLP” peptide binds a portion of the BCR from patients “P” and “E” which is 
not accessible on cells and not present on serum IgM. The binding of “QSRPLLP” 
peptide-phage clone to patients “P” and “E” BCRs using an ELISA method suggest that it 
is possible to use a Phage Display Peptide Library to select for peptides unique to the 
BCRs of patients with CLL.  
The two strategies used in our work showed that the strategy used for negative 
selection is the critical component in the search for peptides binding specifically to the 
antigen binding site of the BCRs. This can be improved by increasing the number of 
subtractions with BCRs from CLL cells from another patient. Alternative, since CLL 
cells secret polyreactive immunoglobulins that bind self antigens with low binding 
affinities [38], it is possible that the BCR antigen binding site is bound to self antigens. 
Thus, the antigen binding site of the BCR could be blocked and this would hinder the 
selection of peptides binding to the antigen binding site of the targeted BCR. A solution 
to this problem would be to reduce the pH of captured BCRs, without compromising the 
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structural integrity of the BCR, thereby detaching any bound self antigens and then 
incubating with the phage display peptide library. 
Targeting the BCR of CLL cells will ensure that only those cells are affected and 
this approach still remains a possible target for treatment of CLL. Discovered patient-
specific peptides can then be fused with a toxin and used to treat patients with CLL [16, 
49]. 
 An optimized selection strategy for peptides binding to the antigen binding site of 
the BCRs would allow for patients, diagnosed with CLL and with a poor prognosis, to be 
treated early. The use of the peptide-toxin complex would have an immunotherapeutic 
advantage in killing CLL cells with less non-specific toxicity. 
Sequence analysis reveals the use of similar restricted repertoire of 
immunoglobulin VH DJH and VLJL genes among CLL patients and shows that some CLL 
patients have similar stereotypic HCDR3 and LCDR3 motifs [3]. The antigen binding 
sites of the BCRs, therefore, recognize the same antigenic epitope [24, 29, 41, 60] and a 
peptide targeting the antigen binding site of a patients’ BCR could also be tested on 
patients expressing the same restricted repertoire of Ig genes.  
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APPENDIX A 
Preparation of reagents used in this study: 
 Tris 1 M pH 9.1- Add 6 grams of Tris base (MW 121 grams per mole) to 40 mL 
of filtered distilled deionized water. Mix well until dissolved. Add 1 M HCl acid 
to adjust to pH 9.1. Add filtered distilled deionized water to bring to a final 
volume of 50 mL. 
 
 Glycine 0.2 M,  HCl pH 2.2, 1% BSA- Dissolve 1.5 grams of glycine (MW 
75.07) to 50 mL of filtered distilled deionized water. Mix well. Add 1 M HCl to 
adjust to pH 2.2. Add 100 milligrams BSA and dissolve it. Add filtered distilled 
deionized water to bring to a final volume of 100 mL. 
 
 20% PEG 8000 (Poly Ethylene Glycol 8000), 2.5 M NaCl- Dissolve 14.6 grams 
of NaCl in 60 mL of filtered distilled deionized water using a stirrer and heat. Add 
filtered distilled deionized water to bring volume to 80 mL. Add 20 grams of 
PEG. Autoclave and mix well to combine separate layers while still warm. Store 
at room temperature. 
 
 1% BSA, 2 mM EDTA in HBSS pH 7.4- Dissolve 0.4 grams of BSA in 40 mL of 
HBSS pH 7.4. Add 160 microliters of 0.6 M EDTA. 
 
 1% Paraformaldehyde (PFA) in HBSS- Add 1 mL of 16% PFA solution to 15 mL 
of HBSS pH 7.4 
 
 LB Broth- Dissolve 12.5 grams of LB broth powder in 500 mL of filtered distilled 
deionized water. Add a magnetic stirrer and autoclave.  
 
 Tetracycline Stock (suspension) - 20 mg/mL in 1:1 Ethanol: Water. Store at -
20
0
C. Vortex before using. 
 
 LB Tetracycline plates- Add 15 grams to 1 liter of LB medium, autoclave and 
cool to <70 
o
C. Add 1mL Tetracycline Stock and pour onto Petri dishes. Store 
plates at 4
0
C. Do not use plates if they are brown or black.  
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 IPTG/Xgal Stock. Mix 1.25 grams IPTG (isopropyl-β-D-galactosidase) and 1 
gram Xgal (5-Bromo-4-chloro-3-indolyl-β-D-galactoside) in 25 mL DMF 
(dimethyl formamide). Store solution at -20
0
C. 
 IPTG/ Xgal LB Plate Agar- Dissolve 12.5 grams of LB broth powder and 7.5 
grams of bacteriological agar in 500 mL of filtered distilled deionized water. Add 
a magnetic stirrer and autoclave. Pour 20 mL into each petri dish and allow it to 
cool and solidify. 
 
 Phage top agar- Dissolve 12.5 grams of LB broth powder and 3.5grams of 
bacteriological agar in 500 mL of filtered distilled deionized water. Add a 
magnetic stirrer and autoclave. Pour 3 mL to sterile glass tubes to be used for 
phage titrations. 
 
 Iodide buffer (10 mM Tris HCl pH 8, 1 mM EDTA, 4 M Sodium Iodide). Weigh 
29.978 grams of Sodium Iodide and add to a 250 mL glass beaker. Add 100 
microliters of 0.5 M EDTA solution. Add 500 microliters of 1 M Tris solution. 
Bring volume up to 50 mL using filtered distilled deionized water 
 
 TBS- 50 mM Tris-HCL (pH7.5), 150 mM NaCl. Autoclave and store at room 
temperature.  
 
 Blocking Buffer for phage panning- 0.1 M NaHCO3 (pH 8.6), 5 mg/ml BSA. 
Filter sterilize and store at 4
0
C. 
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